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Amyotrophic lateral sclerosis (ALS) is the most common form of adult onset motor neuron 
disease and is characterized by the progressive degeneration and death of motor neurons.  The 
pathologic mechanisms underlying ALS are poorly understood although our laboratory identified 
decreased levels of transthyretin (TTR), a protein that impacts the retinoid signaling pathway, in 
the cerebrospinal fluid of ALS patients.  Differential expression of retinoid signaling components 
has been reported in ALS patients and transgenic animal models of familial ALS.  We sought to 
further characterize TTR and retinoid signaling proteins in ALS and to evaluate the role of 
retinoid signaling in motor neuron cell death. 
Mass spectrometry and immunoblotting were used to investigate TTR.  
Immunohistochemistry using lumbar spinal cord tissue from ALS patients and non-neurologic 
disease controls was used to characterize retinoid signaling pathway proteins.  Spinal cord tissue 
homogenates were used for co-immunoprecipitation studies and electrophoretic mobility shift 
assays.  Motor neuron-enriched cultures established from embryonic day 14 rats were utilized for 
in vitro studies.  RAR-mediated signaling was modulated with pan-agonists and isotype-specific 
agents and hydrogen peroxide used to model oxidative stress/injury. 
Altered post-translational modifications and high molecular weight species of the TTR 
protein were observed in ALS.  Cellular retinoic acid binding protein-II (CRABP-II) and retinoic 
acid receptor beta (RARβ) exhibited increased nuclear localization in motor neurons of sporadic 
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ALS patients.  Protein-protein interactions (between CRABP-II and RARα or RARβ) did not 
differ although retinoic acid response element binding was increased in ALS as compared to 
controls.  Treatment with a pan-RAR or RARβ-specific agonist significantly decreased oxidative 
stress-induced motor neuron cell death in vitro and genes downstream of RARβ were increased 
with treatment. 
Our results indicate that TTR genetic polymorphisms do not represent a novel 
susceptibility factor for ALS, although protein modification and aggregation appear to be altered 
in ALS.  Localization of proteins of the retinoid signaling pathway is altered in ALS patients and 
these changes translate to the transcriptional level.  Our in vitro work indicates that stimulating 
the RARs (particularly RARβ) is neuroprotective and that pharmacologic agents that target this 
nuclear receptor may be of value in slowing the progression of ALS. 
 
 
 vi 
TABLE OF CONTENTS 
PREFACE ................................................................................................................................. XVI 
1.0 INTRODUCTION ........................................................................................................ 1 
1.1 THE NERVOUS SYSTEM ................................................................................. 1 
1.1.1 Cells and Synapses ........................................................................................... 1 
1.1.2 Central Nervous System .................................................................................. 3 
1.1.3 Brain Overview and Functions ....................................................................... 4 
1.1.4 Spinal Cord Overview and Functions ............................................................ 6 
1.2 THE MOTOR SYSTEM ..................................................................................... 9 
1.2.1 The Motor Pathway ....................................................................................... 11 
1.2.2 Motor Neurons ............................................................................................... 11 
1.2.3 Neuromuscular Junction ............................................................................... 14 
1.3 MOTOR NEURON DISEASE ......................................................................... 16 
1.4 AMYOTROPHIC LATERAL SCLEROSIS .................................................. 17 
1.4.1 Epidemiology .................................................................................................. 18 
1.4.2 Clinical Presentation and Affected CNS Regions ....................................... 18 
1.4.3 Diagnosis of Probable ALS ........................................................................... 20 
1.4.4 Proposed Underlying Mechanisms ............................................................... 21 
1.4.5 Genetics........................................................................................................... 24 
 vii 
1.4.6 Model Systems................................................................................................ 26 
1.4.7 Current and Developing Therapies.............................................................. 27 
1.5 PROTEOMICS AND BIOMARKERS............................................................ 31 
1.5.1 Proteomics ...................................................................................................... 31 
1.5.2 Samples and Techniques for Biomarker Identification ............................. 32 
1.5.3 Value of Biomarkers ...................................................................................... 33 
1.5.4 Important Considerations in Biomarker Discovery ................................... 37 
2.0 EVALUATION OF TRANSTHYRETIN AS A BIOMARKER OF ALS ............ 41 
2.1 ABSTRACT........................................................................................................ 41 
2.2 INTRODUCTION ............................................................................................. 42 
2.2.1 Identification of TTR..................................................................................... 42 
2.2.2 Biological Functions ...................................................................................... 43 
2.2.3 Links to Disease ............................................................................................. 44 
2.2.4 Post-translational Protein Modifications ..................................................... 44 
2.2.5 Study Objectives ............................................................................................ 45 
2.3 MATERIALS AND METHODS ...................................................................... 46 
2.3.1 Collection and Storage of Cerebrospinal Fluid .......................................... 46 
2.3.2 ELISA ............................................................................................................. 46 
2.3.3 Identification of Genetic Polymorphisms .................................................... 47 
2.3.4 Detection of Post-Translational Protein Modifications .............................. 47 
2.3.5 MALDI-TOF-MS Analysis ........................................................................... 48 
2.3.6 Immunoblotting ............................................................................................. 49 
2.3.7 Statistical Analysis ......................................................................................... 49 
 viii 
2.4 RESULTS ........................................................................................................... 49 
2.4.1 Genetic variations can be detected via mass spectrometry ........................ 49 
2.4.2 Total TTR levels do not change over the course of the disease ................. 51 
2.4.3 Oxidative modifications of TTR can be detected via mass spectrometry 
and are altered with different storage conditions ................................................... 52 
2.4.4 High molecular weight forms of TTR are present in the CSF of ALS 
patients ........................................................................................................................ 57 
2.5 DISCUSSION ..................................................................................................... 59 
3.0 RETINOID SIGNALING ALTERATIONS IN ALS PATIENT TISSUE ........... 65 
3.1 ABSTRACT........................................................................................................ 65 
3.2 INTRODUCTION ............................................................................................. 66 
3.2.1 Overview of the Retinoid Signaling Pathway.............................................. 66 
3.2.2 Role in CNS Development ............................................................................. 69 
3.2.3 Roles in Adulthood ........................................................................................ 70 
3.2.4 Connections to ALS ....................................................................................... 72 
3.2.5 Study Objectives ............................................................................................ 74 
3.3 MATERIALS AND METHODS ...................................................................... 74 
3.3.1 Subjects ........................................................................................................... 74 
3.3.2 Antibodies ....................................................................................................... 75 
3.3.3 Tissue Homogenates and Protein Extraction .............................................. 75 
3.3.4 Immunohistochemistry and TUNEL staining ............................................. 77 
3.3.5 Protein-Protein Interactions ......................................................................... 78 
3.3.6 Immunoblot .................................................................................................... 78 
 ix 
3.3.7 Electrophoretic Mobility Shift Assay ........................................................... 79 
3.3.8 Statistical Methods ........................................................................................ 79 
3.4 RESULTS ........................................................................................................... 81 
3.4.1 Subcellular distribution of CRABP-II is altered in sporadic ALS spinal 
cord motor neurons .................................................................................................... 81 
3.4.2 RARβ immunoreactivity is significantly increased in motor neuron nuclei 
of sporadic ALS patients and does not correlate with TUNEL, activated caspase-
3 or TDP-43 staining .................................................................................................. 84 
3.4.3 Protein interactions between CRABP-II and the nuclear receptors do not 
differ between ALS and control groups ................................................................... 90 
3.4.4 Retinoic acid response element binding in spinal cord tissue homogenates 
is increased in ALS as compared to controls ........................................................... 92 
3.5 DISCUSSION ..................................................................................................... 94 
4.0 RETINOIC ACID RECEPTOR-MEDIATED SIGNALING IN MOTOR 
NEURONS ................................................................................................................................. 100 
4.1 ABSTRACT...................................................................................................... 100 
4.2 INTRODUCTION ........................................................................................... 101 
4.2.1 Retinoid Signaling and Limitations of Human Study .............................. 101 
4.2.2 Oxidative Stress ........................................................................................... 102 
4.2.3 Study Objectives .......................................................................................... 103 
4.3 MATERIALS AND METHODS .................................................................... 104 
4.3.1 Motor Neuron-Enriched Culture System .................................................. 104 
4.3.2 RA Pathway Modulators ............................................................................. 104 
 x 
4.3.3 RNA Extraction ........................................................................................... 105 
4.3.4 Quantitative Polymerase Chain Reaction ................................................. 105 
4.3.5 Immunofluorescence ................................................................................... 106 
4.3.6 Cell Viability/Live Cell Imaging ................................................................. 106 
4.3.7 Statistical Analysis ....................................................................................... 107 
4.4 RESULTS ......................................................................................................... 107 
4.4.1 Expression of RARs in primary cultures .................................................. 107 
4.4.2 Absence of RA in media results in decreased motor neuron cell viability
 111 
4.4.3 Stimulating the RARs significantly delays oxidative-induced cell death 114 
4.4.4 Downstream targets are modulated by agonists ....................................... 119 
4.5 DISCUSSION ................................................................................................... 121 
5.0 FUTURE DIRECTIONS AND CONCLUDING REMARKS ............................. 126 
5.1 ADDITIONAL TTR STUDIES ...................................................................... 126 
5.2 TISSUE-BASED WORK ................................................................................ 129 
5.3 IN VITRO STUDIES ....................................................................................... 130 
5.3.1 Investigation of other ALS-relevant toxins ............................................... 130 
5.3.2 Hypoxia ......................................................................................................... 131 
5.3.3 Neurite outgrowth and regeneration ......................................................... 133 
5.3.4 Non-genomic impact of retinoid signaling ................................................. 134 
5.3.5 Microarray analysis of downstream genes ................................................ 134 
5.3.6 Role and effects of glial cells ....................................................................... 135 
5.3.7 Investigation of other potential biomarkers .............................................. 135 
 xi 
5.3.8 Primary cultures from transgenic mutant SOD1 or mutant TDP-43 rats
 136 
5.4 CONCLUDING REMARKS .......................................................................... 136 
BIBLIOGRAPHY ..................................................................................................................... 139 
 xii 
 LIST OF TABLES 
 
Table 1.  Types of Motor Neuron Disease .................................................................................... 17 
Table 2.  Pathological Features Observed in ALS ........................................................................ 20 
Table 3.  Reported Genes in Familial ALS/MND ........................................................................ 25 
Table 4.  Storage Conditions Utilized to Determine the Relationship of Temperature to Protein 
Modifications ................................................................................................................................ 57 
Table 5.  Cases Utilized for the Human Tissue-Based Study ....................................................... 80 
Table 6.  Primers Utilized for In Vitro Experiments ................................................................... 110 
 xiii 
LIST OF FIGURES 
 
Figure 1.  Schematic Overview of the Nervous System ................................................................. 2 
Figure 2.  Neuronal Synapse ........................................................................................................... 3 
Figure 3.  Midsagittal View of the Brain ........................................................................................ 6 
Figure 4.  Spinal Cord Anatomy ..................................................................................................... 8 
Figure 5.  Cross-Sectional View of the Spinal Cord ....................................................................... 9 
Figure 6.  The Motor Homunculus ............................................................................................... 10 
Figure 7.  Upper and Lower Motor Neurons of the Human Motor System.................................. 13 
Figure 8.  The Neuromuscular Junction ........................................................................................ 15 
Figure 9.  Proposed Mechanisms Underlying ALS ...................................................................... 22 
Figure 10.  Susceptibility of Motor Neurons ................................................................................ 23 
Figure 11.  Potential Uses of Biomarkers ..................................................................................... 34 
Figure 12.  Proteomic Biomarker Discovery Efforts for ALS ...................................................... 35 
Figure 13.  Deciphering ALS from Healthy and Disease Controls by Mass Spectrometry ......... 39 
Figure 14.  Reduction of TTR Protein Modifications with TCEP ................................................ 50 
Figure 15.  TTR Spectra Following TCEP-Reduction.................................................................. 51 
Figure 16.  Overall Levels of TTR Do Not Change Over the Course of the Disease................... 52 
Figure 17.  Post-translational Modifications of TTR are Detectable via Mass Spectrometry ...... 53 
 xiv 
Figure 18.  Oxidative Post-translational Protein Modifications are Altered in ALS Patients ...... 54 
Figure 19.  MALDI-TOF-MS of CSF Stored at Various Temperatures....................................... 56 
Figure 20.  Immunoblot Analysis of CSF Stored at Different Temperatures ............................... 56 
Figure 21.  Denaturing and Non-Denaturing Gel Electrophoresis for TTR ................................. 58 
Figure 22.  Potential Roles of TTR in ALS .................................................................................. 64 
Figure 23.  Retinoid Signaling Overview ..................................................................................... 68 
Figure 24.  Retinoic Acid in Interneuron and Motor Neuron Development ................................. 70 
Figure 25.  RA-Mediated Responses Associated with Injury or Degeneration in the Adult CNS 72 
Figure 26.  Immunohistochemistry Analysis of Cytoplasmic Binding Proteins in Human Spinal 
Cord Tissue ................................................................................................................................... 83 
Figure 27.  Immunohistochemistry Analysis of RAR Proteins in Human Spinal Cord Tissue .... 86 
Figure 28.  Immunohistochemical Analysis of RARβ and TUNEL in Human Spinal Cord ........ 87 
Figure 29.  Immunohistochemical Analysis of RARβ and Activated Caspase-3 in Human Spinal 
Cord............................................................................................................................................... 88 
Figure 30.  Immunohistochemical Analysis of RARβ and TDP-43 in Human Spinal Cord ........ 89 
Figure 31.  Protein-Protein Interactions in Nuclear-Enriched Fractions from Human Lumbar 
Spinal Cord ................................................................................................................................... 91 
Figure 32.  RARE Binding in Spinal Cord Tissue Homogenates ................................................. 93 
Figure 33.  Schematic Representation of Retinoid Signaling in Familial and Sporadic ALS ...... 99 
Figure 34.  β3-tubulin Expression and Motor Neuron Culture Purity ........................................ 108 
Figure 35.  In Vitro RAR Expression.......................................................................................... 109 
Figure 36.  Characterization of RAR Protein Expression ........................................................... 111 
Figure 37.  Hydrogen Peroxide Dose Response Curve............................................................... 112 
 xv 
Figure 38.  Decreased Cell Death in the Presence of RA ........................................................... 113 
Figure 39.  ATRA Treatment Decreases Oxidative-Induced Motor Neuron Cell Death ........... 115 
Figure 40.  Localization of RARα and RARβ with and without ATRA Treatment ................... 116 
Figure 41.  RARβ Modulation .................................................................................................... 118 
Figure 42.  Treatment with RA Pathway Modulators after Toxin .............................................. 119 
Figure 43.  Q-PCR Analysis of Downstream Genes of the RARs.............................................. 120 
Figure 44.  TTR and the Transcriptional Impact of Nuclear RARβ ........................................... 138 
 xvi 
PREFACE 
When I decided to apply to graduate school, I knew that the journey would be filled with 
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friends instead of just colleagues.  My mentor relationship with David Lacomis was another 
invaluable aspect of my graduate training.  The opportunity to attend Multidisciplinary Clinics 
with Dr. Lacomis and to see patients with ALS first-hand provided perspective and fueled my 
passion to make a difference in the lives of these individuals.  I greatly admire Dr. Lacomis and 
the relationship he has established with his patients along with his humor and genuine interest in 
my training.  
In addition to these relationships and as a graduate student in the Cellular and Molecular 
Pathology (CMP) Program, there were a number of other people that helped me along this 
journey and made its completion possible.  Wendy Mars, our program director, was a critical 
counselor, instructor and advocate.  Shari Tipton kept me organized and was constantly available 
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Department of Pathology has also provided some form of advice, encouragement or assistance, I 
think the majority of the thanks for this should be attributed to George Michalopoulos for 
recruiting these excellent faculty members and creating the collaborative and scientifically-rich 
working environment in which I was fortunate enough to train.  The administrative staff of the 
School of Medicine in general was also of great assistance including Cindy Duffy, Veronica 
Cardamone, Carol Williams, Claire Gauss and Jennifer Walker. 
My four committee members (Charleen Chu, Satdarshan Monga, Kacey Marra and 
Michael Zigmond) were another critical component of my training.  Their guidance, support and 
commitment to my development as an independent scientist were beyond what I could have 
asked.  In addition, these individuals served as collaborators throughout my training.  Dr. Monga 
kindly offered liver extracts for use as positive controls.  Dr. Marra and Han Li provided hypoxia 
chambers for studies investigating non-physiologic oxygenation.  Dr. Chu and Sam Cherra 
assisted with morphological assessments of neuronal processes.  
I have also been extremely fortunate to collaborate with a number of exceptional 
scientists (in addition to the individuals mentioned above).  The laboratory of Brent Harris 
including David Graber and Christopher Cogbill at Dartmouth University opened their 
laboratory doors to me and spent an intense day and a half teaching me how to isolate and culture 
primary motor neurons.  At the University of Pittsburgh, Jonette Werley offered invaluable 
assistance and advice concerning immunohistochemistry.  Don DeFranco and Marcia Lewis 
allowed me to practice spinal cord isolations while we waited for approval of our IACUC 
protocol.  William Walker and Michelle Wood assisted with gel shift assays and the 
troubleshooting that followed.  Aaron Bell and John Stoops were critical for primer design and 
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Q-PCR.  The laboratory of Johnny Huard, specifically Jonathan Proto, Lauren Drowley, Joe 
Feduska and Mitra Lavasani gave me the opportunity to perform live cell imaging experiments, 
and I am immensely grateful for this assistance as these experiments added a great deal to our in 
vitro work.  
Obviously, research cannot be conducted without funding, and I am grateful for the 
support I received from the Cellular Approaches to Tissue Engineering and Regeneration 
(CATER; NIH T32 EB001026) and Clinical and Translational Science Institute (CTSI; NIH T32 
05 TL1 RR024155-02) Training Grants.  I would especially like to thank Alan Russell and Marla 
Harris for their assistance during my time as a CATER fellow.  Nicole Fowler, Benjamin 
Huffman, Galen Switzer, Mark Roberts and Wishwa Kapoor deserve my thanks for their help 
during my time as a member of the CTSI program. 
Along my climb, I had the opportunity to reflect upon teachers from my past that aided in 
getting me to this point.  Two of these previous mentors deserve my most sincere and heart-felt 
thanks.  William Valilik, my high school biology professor, somehow knew that I would end up 
in a Ph.D. program before I knew they existed and encouraged me to apply for training programs 
as a high school student.  My undergraduate mentor, John Simpson, gave me my first experience 
conducting research.  His mentorship and friendship prepared me for what I would experience in 
graduate school, and I regret that he could not be here at this point in my career as having his 
approval always meant so much to me. 
At times along this climb, I felt as if I would not be able to hold on much longer, that 
there was really no way for me to progress or that even if I moved forward, the obstacles in front 
of me were too great to move.  At these critical times, my involvement with the Western 
Pennsylvania/West Virginia Chapter of the ALS Association served as a source of inspiration.  
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be more grateful to Brian McMahon and my brother Chad for sending to me each and every 
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to do all of this all over again if for no other reason than to have these people become part of my 
life.  Other members of the Royal Blue PSL Softball team (Bart Phillips, Austin Dulak, Brian 
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addition, all of my wonderful and amazing ―non-science‖ friends were instrumental to my 
success, and I could not be more thankful for each and every one of them. 
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beginning and experienced the trials and tribulations of this journey with me are my family.  I 
could not ask for a better, more supportive group of cheerleaders and thank them for believing in 
me and my abilities when I was convinced that I just could not keep going.  My Mom has always 
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graduate school with me and endured things like weekend trips to lab and the whole thesis-
writing process.  It wasn’t always easy for either of us, but coming home to Jared made all the 
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My family has understood my need for a ―thesis room‖ (even when that room extended 
beyond its boundaries to the kitchen table) and that when I said I was almost done I would surely 
still be in graduate school another year.  But most of all, my family has reminded me of what 
truly matters at the end of the day, and I could not be luckier to have them.  Without each and 
every one of these people, I would not have made it to this point in my career/life.  And, 
although there will surely be other mountains to climb and countless other obstacles ahead, it is 
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1.0  INTRODUCTION 
1.1 THE NERVOUS SYSTEM 
The nervous system is a complex and fascinating organ system consisting of neural circuits of 
specialized cells that coordinate, integrate and control all body activities/functions.  In humans, it 
consists of both central and peripheral parts (Figure 1).  The central nervous system (CNS) 
includes the brain, spinal cord and retina while the peripheral nervous system (PNS) includes 
sensory (afferent) and motor (efferent) neurons, clusters of neurons called ganglia and nerves 
which connect these components to each other and to the CNS. 
1.1.1 Cells and Synapses 
Neurons are considered the functional unit of the nervous system and communicate with other 
cells via synapses or membrane-to-membrane junctions that allow for the rapid transmission of 
electrical or chemical signals.  For electrical synapses, there is a direct electrical connection 
between neurons; chemical synapses are more common and more diverse in function (Figure 2) 
[1].  At these junctions, the pre-synaptic cell releases neurotransmitters that depolarize the post-
synaptic cell to cause an influx of calcium (Ca
2+
) ions.  Synaptic communication results in 
excitatory, inhibitory or modulatory effects in the post-synaptic cell depending on the receptors 
to which the neurotransmitter binds.   
 2 
  Importantly, the nervous system includes other specialized glial cells including 
astrocytes, microglia, oligodendrocytes and ependymocytes in the CNS.  Among the most 
important functions of these cells are to support neurons; to supply nutrients to neurons; to 
insulate neurons electrically; to destroy pathogens and remove dead neurons; and to provide 
guidance cues directing the migration of neurons and axons of neurons to their targets [2].  
 
Figure 1.  Schematic Overview of the Nervous System 
The nervous system includes both central and peripheral parts.  The central nervous system 
includes the brain and spinal cord while the peripheral nervous system includes both sensory 
(afferent) and motor (efferent) systems with further subdivisions of the motor pathway into the 
autonomic and somatic nervous systems.  The autonomic nervous system includes sympathetic, 
parasympathetic and enteric systems.  Figure modified from 
http://faculty.clintoncc.suny.edu/faculty/michael.gregory/files/bio%20102/bio%20102%20lectur
es/nervous%20system/nervous1.htm. 
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Figure 2.  Neuronal Synapse 
Neurotransmitters (e.g., glutamate) contained within synaptic vesicles of the pre-synaptic cell 
are released into the synaptic cleft.  Receptors on the post-synaptic cell bind neurotransmitter 
molecules which respond by opening nearby ion channels which results in an influx of calcium 
into the post-synaptic cell (a neuron in this case) and depolarization.  Reuptake pumps located 
on both neuronal and glial cells remove and recycle excess neurotransmitter.  Figure modified 
from http://en.wikipedia.org/wiki/File:Synapse_Illustration_unlabeled.svg. 
1.1.2 Central Nervous System 
The CNS consists of the brain and spinal cord with the brainstem serving as the connection 
between them.  While the brain controls most bodily functions including awareness, thought, 
speech, memory, sensation and movement, the spinal cord serves as a highway for carrying 
signals between the brain and PNS.  In vertebrates, the brain is protected by the skull and the 
spinal cord by the vertebrae, and both are covered by the meninges, three continuous sheets of 
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connective tissue including the pia mater, the arachnoid and the dura mater.  The region between 
the pia and arachnoid mater is filled with cerebrospinal fluid (CSF), a secretion produced by the 
cells of the choroid plexus.  CSF surrounds the brain and spinal cord and circulates throughout 
the CNS through the central cerebrospinal canal of the spinal cord and through the four 
ventricles of the brain.  Eventually, it returns to the blood through veins that drain the brain.  
CSF plays multiple and critical roles in that it acts as a cushion, regulates extracellular fluid, 
allows for the distribution of neuroactive substances and is the ―sink‖ that collects the waste 
products produced by the cells of the brain and spinal cord.  In addition, the brain and spinal cord 
are isolated by the blood-brain barrier, which restricts the movement of microscopic objects (i.e., 
bacteria) and large or hydrophilic molecules from the bloodstream to the interior of the CNS.   
1.1.3 Brain Overview and Functions 
The major structures of the brain are outlined below (Figure 3) and generally consist of the 
hindbrain, midbrain and forebrain.  The hindbrain or rhombencephalon includes the medulla 
oblongata, pons and cerebellum.  The medulla oblongata is interconnected with the cervical 
spinal cord and helps control vital processes like breathing, heart rate and blood pressure.  
Importantly, it carries the corticospinal tract toward the spinal cord.  The pons serves as a bridge 
between the midbrain and the medulla oblongata and is involved in motor control and sensory 
analysis.  The cerebellum consists of two deeply-convoluted hemispheres containing as many 
neurons as the rest of the brain combined, and it functions in the regulation and coordination of 
bodily movements, posture and balance. 
The midbrain (mesencephalon) is located below the hypothalamus and includes the 
tectum and tegmentum.  Together, the midbrain, medulla oblongata and pons are referred to as 
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the brainstem.  This compact structure marks the convergence of multiple pathways that carry 
information to and from the brain to the spinal cord.  Therefore, damage to the brainstem can 
affect multiple functions and, because these fibers do not typically regenerate, such damage can 
result in permanent loss of function. 
The telencephalon and diencephalon make up the human forebrain (prosencephalon) 
which includes the largest part of the brain, the cerebrum.  The cerebrum is divided into the left 
(controls the right side of the body) and right (controls the left side of the body) hemispheres 
which are linked by a mass of fibers called the corpus callosum.  Each hemisphere consists of 
four interconnected lobes (frontal, parietal, temporal and occipital) with distinct functions.  The 
cerebral cortex or gray matter is the external-most layer of the brain and consists predominantly 
of neuronal cell bodies which store and process information.  Myelin-sheathed axonal 
projections of these cells extend to other areas of the brain and body and make up the white 
matter. 
The limbic system, consisting of the thalamus, hypothalamus, amygdala and 
hippocampus, is located within the cerebrum.  The thalamus is a large mass of gray matter 
situated deep in the forebrain with both sensory and motor functions.  Axons from every sensory 
system (except olfaction) synapse here as the last relay site before the information reaches the 
cerebral cortex (parietal, temporal and occipital lobes).  The hypothalamus controls automatic 
functions like emotion, hunger, circadian rhythms and the autonomic nervous system.  In 
addition, it controls the pituitary gland and thereby the release of other hormones.  The amygdala 
is located in the temporal lobe and involved in memory, emotion and fear.  The hippocampus is 
also located within the temporal lobe and plays a critical role in learning and long-term memory. 
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Figure 3.  Midsagittal View of the Brain 
The brain controls most bodily functions and can generally be divided into the hindbrain, 
midbrain and forebrain with distinct structures that comprise each region.  Physical protection 
is provided by the layers of the meninges as well as the skull.  Cerebrospinal fluid is synthesized 
by the cells of the choroid plexus.  Figure modified from 
http://homepage.psy.utexas.edu/homepage/class/Psy332/Salinas/Neuroanatomy/Neuroanat.html. 
1.1.4 Spinal Cord Overview and Functions 
The spinal cord connects to the brain via the brainstem and is physically protected by the 
vertebral bodies that make up the spinal column and the meningeal layers (Figures 4 and 5).  It 
conducts sensory (afferent) information from the PNS (including both somatic and autonomic 
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systems) to the brain and motor (efferent) information (including autonomic efferents) from the 
brain to muscles (skeletal, cardiac and smooth) and glands.  Cranial nerves exit the brainstem 
and nerve roots exit the spinal cord on both sides of the vertebral body.  Nerve roots are located 
ventral in relation to the spinal cord if efferent or dorsal if afferent.  Fibers that carry motor input 
to limbs and fibers that bring sensory information from the limbs to the spinal cord grow together 
to form a mixed (motor and sensory) peripheral nerve.  A portion of the lumbar and all sacral 
nerve roots travel downward into the spinal canal before exiting the spinal cord in a bundle 
called the cauda equina (horse’s tail). 
 Within the spinal cord there are thirty-one pairs of mixed (both sensory and motor axons) 
spinal nerves belonging to different levels according to the region of the body innervated:  1.) 
cervical (8 pairs of nerves that transmit signals from or to parts of the head, neck, shoulders, 
arms and hands), 2.) thoracic (12 pairs of nerves that transmit signals from or to parts of the arms 
and the chest and abdominal areas), 3.) lumbar (5 pairs of nerves that transmit signals from or to 
the legs, feet and some pelvic organs), 4.) sacral (5 pairs of nerves that transmit signals from or 
to the lower back, buttocks, pelvic organs, genital areas and some areas in the legs and feet) and 
5.) coccygeal (1 pair of nerves located at the bottom of the spinal cord).  All sensory axons pass 
into the dorsal root ganglion where their cell bodies are located and then into the spinal cord 
while all motor axons pass into the ventral roots before combining with the sensory axons to 
form the mixed nerves. 
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Figure 4.  Spinal Cord Anatomy 
The spinal cord is protected by the vertebrae and the three meningeal layers.  Fibers exit both 
sides of the spinal cord and their location (dorsal or ventral) depends on the direction of the 
signals they carry (afferent or efferent).  Figure modified from 
http://homepage.psy.utexas.edu/homepage/class/Psy332/Salinas/Neuroanatomy/Neuroanat.html. 
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Figure 5.  Cross-Sectional View of the Spinal Cord 
The cross-sectional view of the spinal cord reveals the characteristic butterfly-shaped pattern 
resulting from the boundary between the gray matter (nerve cell bodies) and the surrounding 
tissue of the white matter.  The location of motor neurons in the ventral horn is highlighted as 
well as the routes of both afferent and efferent axons.  Figure modified from 
http://homepage.psy.utexas.edu/homepage/class/Psy332/Salinas/Neuroanatomy/Neuroanat.html. 
1.2 THE MOTOR SYSTEM 
The motor system is responsible for the generation and control of voluntary and reflex 
movements and is an efferent pathway conducting impulses from the CNS to muscle.  It can be 
divided into (1) the complex central apparatus, including the descending tracts involved in 
control (i.e., the pyramidal system) and the systems involved in initiating and regulating 
movement (the basal ganglia and cerebellum) and (2) the peripheral apparatus, which consists of 
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the anterior horn cell and its peripheral axon, the neuromuscular junction and muscle.  The motor 
innervation of the human body is often represented by a distorted human figure called the motor 
homunculus (Figure 6). 
 
Figure 6.  The Motor Homunculus 
The motor homunculus is a representation of the different body parts controlled by specific 
regions of the motor cortex.  The leg area is located medially, the head and face area laterally 
and the arm and hand area between the leg and face.  The map was determined by stimulating 
different points in the cortex of conscious patients during brain surgery and recording what they 
said they felt.  Figure modified from http://www.harmonicresolution.com/homunculus1.jpeg. 
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1.2.1 The Motor Pathway  
The motor pathway, also called the pyramidal tract or the corticospinal tract, originates in the 
giant pyramidal (or Betz) cells of the precentral gyrus (motor cortex) [3-6].  Long axons extend 
from the motor cortex to the motor cranial nerve nuclei of the midbrain (forming the 
corticomesencephalic tract), pons (forming the corticopontine tract) and medulla oblongata 
(forming the corticobulbar tract) or down to the spinal cord (forming the corticospinal tract).  
Most of the corticospinal fibers (about 85%) cross over to the opposite side in the medulla 
oblongata, a process called pyramidal decussation, forming the lateral corticospinal tract.  The 
remaining 15% of the fibers form the ventral corticospinal tract and cross in the spinal cord.  The 
axons that make-up both of these tracts eventually synapse with another neuron located in the 
ventral horn of the spinal cord.  The corticospinal and corticobulbar fibers are considered the 
pathways for control of voluntary movements and are affected in motor neuron diseases. 
1.2.2 Motor Neurons  
The motor neuron is a specialized type of neuronal cell responsible for controlling muscle 
movement.  A single motor neuron can synapse with one or more muscle fibers; collectively, the 
motor neuron and the muscle fibers to which it connects are called a motor unit.  Both upper and 
lower motor neuron populations exist.  The cell bodies of upper motor neurons (UMNs) are 
located in the motor cortex and their axons carry motor information down the brainstem and 
spinal cord but are not directly responsible for stimulating target muscle (Figure 7).  Rather, the 
axons of these neurons connect (mostly via interneurons but some through direct synapses) with 
lower motor neurons (LMNs).  The cell bodies of LMNs are located in the ventral horn of the 
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spinal cord or in the motor cranial nerve nuclei of the brainstem.  The LMN axonal projections 
leave either the brainstem or spinal cord via motor cranial nerves or anterior roots of the spinal 
nerves, respectively, and terminate at their muscle fiber target.  They are classified as either 
alpha or gamma motor neurons based on the type of muscle they innervate.  Alpha motor 
neurons innervate extrafusal muscle fibers which function in muscle contraction.  Gamma motor 
neurons innervate intrafusal muscle fibers which are involved with muscle spindles and the sense 
of body position.   
The distinction between types of motor neurons is of particular interest in ALS because 
of the observation that different types of motor neurons responsible for innervating different 
subsets of muscle fibers have different susceptibilities to mutated proteins that cause toxicity in 
familial ALS.  More specifically, in two different models of familial ALS, the fast-fatiguable 
motor neurons were found to be affected first with denervation of their target muscles occurring 
prior to symptom onset.  Subsequent retraction of the fast-fatigue-resistant motor neurons 
occurred with the slow type demonstrating partial resistance to toxicity [7, 8].  The latter motor 
neuron population also appeared to demonstrate the ability to reinnervate previously denervated 
regions.   
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Figure 7.  Upper and Lower Motor Neurons of the Human Motor System 
The cell bodies of upper motor neurons originate in the motor cortex with long axons that extend 
and connect (either directly or via interneurons) to lower motor neurons via the corticospinal 
tract.  Lower motor neurons directly innervate target muscle fibers.  Both upper and lower motor 
neuron populations are affected in ALS.  Figure modified from [9]. 
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1.2.3 Neuromuscular Junction  
Motor neurons communicate with skeletal muscle fibers at a specific type of neuroeffector 
junction called the neuromuscular junction (NMJ) (Figure 8).  At this synapse, the axon terminal 
of the motor neuron signals to the motor end plate of a muscle fiber through the release of the 
neurotransmitter acetylcholine (ACh) which ultimately results in muscle contraction.  More 
specifically, glutamate released from the UMNs triggers the depolarization of LMNs which 
results in an action potential that propagates along the axon of the LMN.  In response to this 
action potential, voltage-dependent Ca
2+
 channels open to allow for the influx of Ca
2+
 into the 
motor neuron.  This leads to vesicle docking and fusion such that ACh is released into the 
synaptic cleft.  Nicotinic ACh receptors located on the motor end plate bind the released 
neurotransmitter, increasing the permeability of ion channels that cause sodium (Na
+
) influx and 
potassium (K
+
) efflux.  Local depolarization of the motor end plate (end-plate potential) then 
spreads across the surface of the muscle fiber to transverse tubules (T-tubules), eliciting Ca
2+
 
release from the sarcoplasmic reticulum and initiating muscle contraction.  Importantly, 
remaining ACh is degraded to produce choline and acetic acid by the enzyme 
acetylcholinesterase (AChE).  Choline is then transported back into the presynaptic terminal via 
reuptake receptors such that new ACh molecules can be made. 
Although the effect of a neurotransmitter (i.e., whether it is excitatory, inhibitory or 
modulatory) is typically dependent upon the receptor it binds, the response of a muscle fiber can 
only be excitatory (i.e., contractile).  For muscle relaxation or inhibition of muscle contraction, 
the motor neuron must be inhibited.  It is worth noting that although one motor neuron can 
control multiple muscle cells, each muscle cell only responds to one motor neuron; if a motor 
neuron dies, however, adjacent neurons can sprout to innervate additional muscle fibers.  When 
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this compensatory sprouting capacity is exhausted, normal skeletal muscle function and 
movement are compromised and disease occurs.  In ALS mouse models, connection to the 
muscle at the NMJ is lost prior to motor neuron degeneration or death and the initiation of 
symptoms [7, 8, 10, 11]. 
 
Figure 8.  The Neuromuscular Junction 
Motor neurons communicate with skeletal muscles at the neuromuscular junction.  Release of 
ACh-containing vesicles from the motor neuron ultimately causes calcium release from the 
sarcoplasmic reticulum and muscle contraction.  Figure modified from 
http://www.bio.miami.edu/~cmallery/150/neuro/neuromuscular-sml.jpg. 
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1.3 MOTOR NEURON DISEASE 
Motor neuron diseases (MNDs) are a heterogeneous group of disorders involving the progressive 
degeneration and death of motor neurons located in the brain, brainstem and spinal cord (Table 
1).  As both UMNs and LMNs can be affected, this family of disorders is often classified into 
three major subgroups according to the neuronal population affected:  1.) primary lateral 
sclerosis (PLS) (pure upper (corticospinal) motor neuron involvement), 2.) progressive muscular 
atrophy (PMA) (pure lower (spinal) motor neuron involvement), and 3.) amyotrophic lateral 
sclerosis (ALS) (combined upper and lower motor neuron involvement).  Further discussion will 
focus on ALS. 
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Table 1.  Types of Motor Neuron Disease 
Motor Neuron Disease Affected Neuronal Population Cause 
Primary lateral sclerosis (PLS) upper motor neurons Idiopathic 
 Pseudobulbar palsy bulbar upper motor neurons Idiopathic 
Primary muscular atrophy (PMA) lower motor neurons Idiopathic 
 Progressive bulbar palsy bulbar lower motor neurons Idiopathic 
Amyotrophic lateral sclerosis (ALS) upper and lower motor 
neurons 
Idiopathic and 
Inherited Forms 
Other Motor Neuron Diseases   
 Kennedy’s disease or X-
linked spinal and bulbar 
muscular atrophy (SBMA) 
brainstem and spinal cord 
motor neurons 
CAG repeat in the 
androgen receptor gene 
 Spinal muscular atrophy spinal cord motor neurons Survivor of motor 
neuron (SMN) gene 
mutations 
1.4 AMYOTROPHIC LATERAL SCLEROSIS 
Amyotrophic lateral sclerosis (ALS), commonly referred to as Lou Gehrig’s disease in North 
America, was first described in 1869 by the French neurologist Jean-Martin Charcot as a late-
onset and progressive motor neuron disease [12].  Over 140 years later, the most common adult 
onset motor neuron disease remains poorly understood and effective therapeutic interventions are 
still needed. 
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1.4.1 Epidemiology 
The incidence and prevalence of ALS are 1-2 cases and 4-6 cases per 100,000, respectively, and 
as many as 30,000 Americans have this disease at any given time [13-15].  There is a slight 
gender disparity toward males (1.5 to 1.0 in sporadic cases) although all races and ethnic 
backgrounds can be affected.  The average age of disease onset is 55 years with a median 
survival of approximately 3 years for newly diagnosed patients, although this can vary between 1 
and 20 years [16, 17].  While it is unclear what determines this difference, improved survival and 
slower disease progression have been associated with limb onset (muscles affecting the legs and 
arms are affected initially) while a poorer prognosis and more rapid disease progression typically 
occur with bulbar onset (muscles affecting speech and swallowing are initially affected)  [18]. 
Although the incidence of ALS is regarded as regionally uniform, there are a few regions 
where an elevated occurrence of ALS has been observed.  The largest is the area of Guam where 
the Chamorro people have had an incidence as high as 143 cases per 100,000 people per year of 
a condition called Lytico-Bodig disease which is a combination of ALS, Parkinsonism and 
dementia [19].  Two other areas with increased incidence are the Kii peninsula of Japan and 
West Papua [20, 21].  In addition, although there have been reports of ―clusters‖ of cases 
including three San Francisco 49ers players, over fifty Italian soccer players and husband and 
wife pairs [22-29], these appear to be chance events. 
1.4.2 Clinical Presentation and Affected CNS Regions 
The earliest symptoms of ALS are obvious weakness and/or muscle atrophy followed by 
twitching, cramping or stiffness of affected muscles.  The twitching and cramping associated 
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with dying motor neurons must be accompanied by clinical weakness or atrophy for a diagnosis 
of ALS to be made.   
The site of disease onset determines which part of the body is affected by early 
symptoms.  Approximately 75% of cases experience limb onset disease which manifests as 
awkwardness when walking or running, an increase in the frequency of tripping or stumbling or 
difficulty performing simple tasks that require manual dexterity.  The remaining 25% initially 
notice difficulty speaking clearly (slurred and/or nasal speech, decreased volume) and have 
bulbar onset disease.  Regardless of the location of initial onset, muscle weakness and atrophy 
spread to other parts of the body as the disease progresses.  Patients typically have increasing 
difficulty moving, swallowing (dysphagia) and speaking or forming words (dysathria), and 
denervation of the respiratory muscles and diaphragm is typically the cause of death. 
Clinical features of ALS combine progressive lower motor neuron dysfunction 
characterized by focal and multifocal weakness, muscular atrophy, cramps and fasciculations 
with symptoms of upper motor neuron or corticospinal tract dysfunction (enhanced and 
pathological reflexes and spasticity) [17, 30].  Approximately 15-45% of patients also experience 
what is known as a pseudobulbar affect or emotional lability.  This is characterized by 
uncontrollable laughter, crying or smiling and attributed to the degeneration of bulbar upper 
motor neurons.  It was thought that proper cerebellar and sensory functions were preserved in 
individuals with ALS such that intellect, memory and personality remain intact.  However, it is 
now recognized that patients with ALS may also be affected by cognitive deficits that culminate 
to frontotemporal dementia (FTD) [31].  Control of the eye muscles is the most preserved 
function although this can also be affected in patients with longer disease duration, and bladder 
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and bowel control are usually preserved in ALS.  Some of the pathological features associated 
with ALS and their descriptions are outlined below (Table 2; modified from [9]). 
 
Table 2.  Pathological Features Observed in ALS 
Feature Description/Location 
Motor neuron loss Observed in the cortex, brainstem and spinal cord 
Axonal spheroids Neurofilament aggregates in proximal axons of motor 
neurons 
Bunina bodies Eosinophilic bodies found in the soma of anterior horn 
cells 
Ubiquitinated inclusions Found predominantly in lower motor neurons 
 Skein-like inclusions Threads/filamentous bodies 
 Lewy body-like inclusions Compact, dense bodies 
Hyaline inclusions Large aggregates containing neurofilaments and other 
proteins located in the soma of motor neurons 
1.4.3 Diagnosis of Probable ALS 
Currently, no test can provide a definitive diagnosis of ALS; however, the clinical diagnosis of 
probable ALS is made when both upper and lower motor signs are present [32-34].  Diagnosis is 
based primarily on the signs and symptoms observed by the neurologist along with a battery of 
tests to rule out other (more treatable) diseases.  These can include electromyography (EMG) to 
measure electrical activity in muscles, nerve conduction velocity (NCV) tests to rule out 
peripheral neuropathy or myopathy and magnetic resonance imaging (MRI) to determine 
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whether other conditions like spinal cord tumors, multiple sclerosis or a herniated disk are 
responsible for the symptoms.  Blood and urine samples as well as muscle biopsies may also be 
taken because of the prognosis associated with ALS and the variety of other diseases that can 
mimic ALS at its early stages. 
1.4.4 Proposed Underlying Mechanisms 
Several mechanisms have been implicated in the initiation and propagation of motor neuron 
degeneration (overview in Figure 9) including excitotoxicity, immune activation, mitochondrial 
dysfunction, oxidative stress, altered proteosomal function and apoptosis [16].  In addition, 
prominent disruptions in the neuronal cytoskeleton and the formation of intraneuronal protein 
aggregates have been noted [35].  The most extensively studied of these processes is 
excitotoxicity defined as the ―phenomenon whereby the excitatory action of glutamate and 
related excitatory amino acids becomes transformed into a neuropathological process that can 
rapidly kill central nervous system neurons‖ [36].  Although precise details of this neuronal 
insult are not completely understood, enzymatic cascades and oxidative stress have been 
implicated [37].  However, questions pertaining to the relationship between alterations in these 
pathways and disease onset and progression remain unanswered.  Importantly, non-neuronal 
neighboring cells can enhance damage to motor neurons (reviewed in [38]); contributing to 
excitotoxicity, causing inadequate growth factor signaling and initiating/exacerbating an 
inflammatory response are examples of how these cells can accelerate disease progression.  
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Figure 9.  Proposed Mechanisms Underlying ALS 
A variety of mechanisms are hypothesized to contribute to the motor neuron degeneration and 
death that occurs in ALS.  Exogenous and genetic factors along with a number of other 
processes are believed to play a role.  Non-neuronal cells including both astrocytes and 
microglia contribute to motor neuron cell death as well.  Figure taken from [9]. 
An underlying theme to many of the aforementioned mechanisms is the susceptibility of 
the motor neuron population (Figure 10) which likely arises from a combination of factors.  For 
example, motor neurons are large cells with long axonal processes (up to 1 meter long) that 
extend to distal lower limb muscles [39].  This creates high energy demands and the need for a 
robust cytoskeleton which translates to high mitochondrial activity and a high intracellular 
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content of neurofilament proteins, respectively.  In addition, the lack of certain calcium buffering 
proteins like parvalbumin as well as the low expression of the GluR2 subunit of the AMPA (α-
amino-3-hydroxyl-5-methyl-4-isoxazole-propionate) receptor may result in increased 
vulnerability to calcium-mediated toxic processes following activation of cell surface glutamate 
receptors [40, 41].  Motor neurons also have a high perisomatic expression of the excitatory 
amino acid transporter 2 (EAAT2) and very high intracellular expression of the free radical-
scavenging enzyme SOD1 [42].  This may increase vulnerability in the presence of genetic or 
post-translational alterations that interfere with the proper function of these proteins.  
 
Figure 10.  Susceptibility of Motor Neurons 
Specific features of motor neurons may explain their susceptibility to some of the mechanisms 
thought to underlie the motor neuron cell death that occurs in motor neuron diseases like ALS.  
Figure modified from [42]. 
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1.4.5 Genetics 
Although the majority of ALS cases (over 90%) are idiopathic in nature, the list of genes 
associated with the 10% of cases with a genetic component (familial ALS) continues to grow 
(reviewed in [38] and [43]).  Inheritance in familial ALS is typically autosomal dominant, but 
some autosomal recessive pedigrees have been described [44-49].  A current list of the genes in 
which mutations cause motor neuron degeneration is provided in Table 3.  The chromosomal loci 
associated with ALS-like motor neuron diseases have been defined as ALS1 through ALS11; 
ALS with frontotemporal dementia (ALS-FTD) and ALS-FTD coupled with Parkinson’s disease 
(ALS-FTDP) are included.  As described in the references listed below, the majority of these 
mutations are rare and most will not be discussed further. 
The 17-year old discovery linking mutations in the gene encoding copper/zinc superoxide 
dismustase (SOD1) to ALS had a major impact in the field [50].  Although SOD1 mutations (of 
which there are over 122) are the most common form of inherited ALS (accounting for 
approximately 1 in 10 familial cases), they account for less than 2% of total cases.  Intensive 
research efforts have focused on these mutations with various in vitro and transgenic animal 
models developed as the clinical features of SOD1-linked ALS are indistinguishable from ALS 
without SOD1 mutations (with the exception that the former has a slight tendency to begin in the 
limbs rather than the bulbar region) [51].  Although the pathways leading to the specific motor 
neuron degeneration in the presence of SOD1 mutations have not been fully identified, this 
enzyme is highly conserved throughout evolution, ubiquitously expressed (constituting 
approximately 1% of total cytosolic protein) and responsible for converting superoxide radicals 
to hydrogen peroxide which is subsequently converted to water by either catalase or glutathione 
peroxidase.  The proposed pathogenetic mechanisms underlying the toxic gain of function 
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associated with SOD1 mutations include oxidative stress, glutamate excitotoxicity, neurofilament 
disorganization, copper toxicity and apoptotic cell death [52]. 
 
Table 3.  Reported Genes in Familial ALS/MND 
Disease Name Gene Chromosome References 
Adult onset dominant typical ALS 
ALS1 SOD1* 21q [50, 53] 
ALS3 Unknown 18q [54] 
ALS6 FUS/TLS 16p [55-59] 
ALS7 Unknown 20p [59] 
Adult onset dominant atypical ALS 
ALS8 VAPB 20q [60, 61] 
ALS9 Angiogenin 14q [62, 63] 
ALS10 TDP-43 1p [64] 
ALS11 FIG4 6q [65] 
ALS-FTD1 Unknown 9q [66] 
ALS-FTD2 Unknown 9p [67] 
ALS-FTD3 CHMP2B 2p [68] 
ALS-FTDP MAPT 17q [69] 
Progressive LMN disease DCTN1 2p [70] 
Juvenile onset dominant ALS 
ALS4 Senataxin 9q [71, 72] 
Juvenile onset recessive ALS 
ALS2 Alsin 2q [47, 49, 73] 
ALS5 Unknown 15q [48] 
SOD1, superoxide dismutase 1; FUS/TLS, fused in sarcoma/translocated in liposarcoma; VAPB, 
vesicle-associated membrane protein B; TDP-43, transactive response DNA-binding protein 43; 
FIG4, factor-induced gene 4 protein; FTD, frontotemporal dementia; CHMP2B, charged 
multivesicular body protein 2B; FTDP, frontotemporal dementia/parkinsonism; MAPT, 
microtubule-associated protein tau; DCTN1, dynactin1; *, the D90A SOD1 mutation can be 
either recessive or dominant [74] 
The most recent discovery in ALS genetics was the identification of mutations in FUS 
(Fused in Sarcoma, ALS6) or TLS (translocated in liposarcoma) as the cause of approximately 1 
in 20 cases of familial ALS [55, 56].  This protein is involved in RNA processing and normally 
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localized to the nucleus as is observed with transactive response DNA-binding protein 43 (TDP-
43).  Interestingly, mutant forms of both FUS/TLS and TDP-43 are found in the cytoplasm rather 
than the nucleus suggesting a similar pathogenetic mechanism.  That is, alterations in RNA 
processing may be a common theme in the pathogenesis of ALS [75]. 
Several genome-wide association studies have also been conducted in ALS [76-82] 
although inconsistent and/or negative results have been obtained potentially as a result of small 
sample sizes.  In spite of this limitation, two themes in underlying pathogenesis were further 
supported.  That is, identification of polymorphisms in the kinesin-associated protein 3 (KIFAP3) 
and elongator protein 3 (ELP3) genes implies that axonal transport and RNA metabolism, 
respectively, impact the disease process [80, 82]. 
1.4.6 Model Systems 
As may be expected from the idiopathic nature of the majority of ALS cases, the model systems 
utilized to study this disease are based on the above-mentioned genetic linkages.  In particular, 
the lack of mechanistic differences between SOD1- and non-SOD1-linked forms of ALS has 
provided rationale for the most commonly-used animal models of the disease.  Overexpression of 
mutant SOD1 protein in rodents leads to a neurodegenerative disease that is similar to what is 
observed in the human condition [83-88].  Interestingly, each model of ALS is consistent and 
distinct with a given mutation (although some variation due to the number of copies of the 
transgene in the animal model does occur), and they vary in their age at onset, disease 
progression and particular histopathological features, thereby mimicking the diversity of 
phenotypes observed in human cases [43].  It was thought that effective therapies in the SOD1 
animal models would translate to the sporadic condition in humans.  Unfortunately, this has not 
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been the case as there are many instances in which agents that have modified the disease process 
in animal models have failed in clinical trials.  Nevertheless, the importance of this model system 
cannot be overlooked particularly with respect to the finding that the toxicity of SOD1 mutations 
is non-cell autonomous such that motor neuron toxicity requires damage from mutant SOD1 
acting within non-neuronal cells [89-92]. 
A number of other models have also been generated.  For instance, two groups generated 
an alsin knockout mouse, but no major motor deficits consistent with ALS or MND in general 
were observed [93, 94].  No rodent models for vesicle-associated membrane protein B (VAPB) 
have been generated although male mutants in Drosophila melanogaster (D. melanogaster) die 
in early larva stage and show severe motor deficits along with severely compromised synaptic 
microtubule assembly [95].  Both microtubule-associated protein tau (MAPT) and dynactin1 
(DCTN1) models exist.  Transgenic mice overexpressing different human tau isoforms in 
neurons experience age-dependent CNS pathology including axonal degeneration in the brain 
and spinal cord, progressive motor disturbances and behavioral impairments [96-99].  Transgenic 
mice overexpressing the p150 subunit of dynactin develop a late onset, progressive motor neuron 
disease [100] and studies in D. melanogaster indicate dynactin promotes synapse stability at the 
NMJ [101].  Finally, gain and loss of function studies using TDP-43 mutations linked to ALS are 
being performed in zebrafish models and will undoubtedly provide novel insight into the role of 
this protein in ALS/MND [102] as will a recently established transgenic rat model [103]. 
1.4.7  Current and Developing Therapies 
There is currently only one Food and Drug Administration (FDA)-approved pharmacologic 
agent designed for the treatment of ALS.  Riluzole (or rilutek) functions as a glutamate 
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antagonist and was first approved for clinical use over ten years ago [104].  Since that time, a 
modest increase (about 3 months) in survival has been demonstrated [104-106] and mortality 
rates were reduced by 23% and 15% at 6 and 12 months, respectively [107].  Recent studies have 
shown that patients receive the maximal benefit when the drug is initiated early in the course of 
disease [108].  In addition, riluzole may be most useful with initial and less severe cases of ALS 
as no effect on overall survival or rate of deterioration of muscle strength were noted in patients 
with a forced vital capacity less than 60% of predicted or over 75 years of age [109, 110].  
Riluzole side effects exist, though these are not common and generally reversible after stopping 
the drug [111], while long-term neurotoxic effects remain unclear. 
 The predictability with respect to disease onset, duration and endpoint times in SOD1 
transgenic animals makes them ideal (at least in theory) models for evaluating potential ALS 
therapeutics.  In fact, over 150 different potential therapeutic agents or strategies have been 
tested in this model according to published trials (outlined in [112]).  These include antioxidants, 
anti-glutamatergic agents, anti-aggregation compounds, anti-apoptotics, immunomodulatory 
drugs, neurotrophic factors, compounds that target non-glutamatergic neurotransmission, gene 
and antisense therapies (both viral and non-viral delivery methods), cell replacement strategies 
and combination treatments.  Unfortunately, agents that modified the disease in the animal model 
have failed to successfully translate to patients, most likely for a multitude of reasons [113-115].  
In an attempt to standardize the translational research conducted in ALS transgenics, a set of 
international guidelines addressing study design, conduct and interpretation have been 
established [116, 117].  Recommendations include matching of gender, litter, genetic 
background, transgene copy number, clinical onset and endpoint criteria.  Importantly, studies 
involving animals treated at pre-symptomatic stages are to be distinguished from those with 
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direct applications to humans (those involving treatment after symptom onset) [116].  The 
following paragraphs will highlight some of the more current and/or ongoing trials for ALS with 
particular emphasis on those that have advanced to later clinical phases. 
Although previous growth factor therapies have failed to prolong survival in transgenic 
ALS mice and patients with ALS (potentially as a result of limitations related to CNS delivery 
and sustained quality), reduced expression of vascular endothelial growth factor (VEGF) has 
been shown to cause motor neuron degeneration in mice [118] and systemic delivery delayed 
onset and death in mutant SOD1 mice [119].  In addition, intracerebroventricular (i.c.v.) 
administration of recombinant VEGF was able to attenuate disease in the mutant SOD1 rat 
model of ALS [120].  In this study, VEGF was shown to have direct neuroprotective effects on 
motor neurons in vivo and was able to preserve NMJs after being anterogradely transported 
following i.c.v. delivery.  Safety trials in humans are currently ongoing. 
An antisense oligonucleotide (ASO) therapy for patients with SOD1-linked familial ALS 
is also currently in Phase I clinical trials (ClinicalTrials.gov Identifier:  NCT01041222).  In 
rodent models, this treatment was shown to double survival following symptom onset [121].  In 
primates, the potential target cell effect (uptake by microglia) was identified 13 weeks after the 
ASO was administered.  In the human study, an intrathecal infusion using an external pump is 
being used.  
Increasing interest in stem cell-based therapies has developed particularly as the role of 
non-neuronal cells has become apparent.  In theory, replacing these supporting cells may be 
more feasible than replacing motor neurons.  In animal models, the transplantation of glial 
progenitor cells had beneficial effects [122] although the impact of migroglial cells in this model 
is still somewhat unclear [123-125].  However, there is currently a Phase I clinical trial to 
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determine the safety of neural progenitor cell transplantation into the spinal cord as tumor 
formation was not observed in animal models [126].  Similarly, the differentiation of induced 
pluripotent stem (iPS) cells to motor neurons using fibroblasts from an 82-year old patient with 
familial ALS has provided additional possibilities for disease modeling, drug discovery and 
autologous cell replacement therapies [127]. 
In a previous Italian study, a marked delay in disease progression (as assessed by a 
quality of life scale and measures of muscle strength and pulmonary function) was observed in 
patients with ALS with daily doses of lithium [128].  However, a combination trial of riluzole 
and lithium was recently terminated early as the dramatic effects observed in this study could not 
be repeated [129].  However, other drug trials remain promising.  Ceftriaxone is currently being 
evaluated for its effect on human ALS in a multi-center clinical trial sponsored by Massachusetts 
General Hospital and the National Institute of Neurological Disorders and Stroke (NINDS) after 
showing promise in mutant SOD1 mice [130].  This antioxidant may increase the expression of 
excitatory amino acid transporter 2 (EAAT2), the glial glutamate transporter found to be down-
regulated or lost in patients with ALS and in rodent models [130].   
In addition, KNS-760704 developed by Knopp Neurosciences, Inc. is now moving to 
Phase III clinical trials after the first dose-dependent effect in patients was observed in Phase II 
trials that included over 100 subjects (ClinicalTrials.gov Identifiers:  NCT00647296 and 
NCT00931944).  This small molecule is the optical enantiomer of pramipexole but has reduced 
dopamine receptor affinity [131, 132].  This has allowed the dopamine receptor-independent 
neuroprotective properties of KNS-760704 to be evaluated over a broader dose range with 
exciting results.   
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The number of ongoing clinical trials in sporadic ALS is encouraging, and the results of 
these and other trials will be highly anticipated by scientists, clinicians and especially the 
patients and families affected by this disease.    
1.5 PROTEOMICS AND BIOMARKERS 
1.5.1 Proteomics 
The field of proteomics has progressed rapidly in recent years as it seeks to identify the 
functional consequences of disease-related genetic aberrations at the level of the protein.  
Defined as the study of the total protein complement of an organelle, cell, tissue or entire 
organism [133], proteomics is a multi-faceted approach used to investigate protein expression 
and post-translational modification as well as protein interactions, organization and function 
[134].  Although limitations and technical hurdles have been encountered, proteomic studies 
have provided unparalleled information with regard to cellular biology and underlying disease 
mechanisms [134].  Additionally, the application of specific techniques such as two-dimensional 
(2-D) gel electrophoresis and/or mass spectrometry promises to uncover biomarkers critical to 
differentiating normal from disease states.  In combination with computer-based algorithms, 
these characteristic biomarkers can, in turn, be used to objectively measure and evaluate normal 
biological processes, pathological conditions or pharmacologic responses [135].  However it 
must be stressed that proteomics has yet to achieve these outcomes in validated studies for any 
pathological condition. 
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1.5.2 Samples and Techniques for Biomarker Identification 
Most proteomics-based research utilizes accessible biological fluids like blood, saliva, synovial 
fluid or urine.  In addition, CSF has been analyzed for proteins to detect diseases ranging from 
Creutzfeldt-Jakob disease [136] to leptomeningeal metastases in breast cancer patients [137].  
For identification of biomarkers of neurodegenerative diseases, it is thought that the use of CSF 
may better reflect proximal disease-specific molecular events. 
 In general, the types of techniques used for biomarker discovery can be classified into 
gel-based, mass spectrometry-based and antibody/protein-based approaches.  However, 
multidimensional fractionation techniques, including various combinations of two dimensional 
gel electrophoresis (2D-GE), liquid chromatography (LC) and hybrid mass spectrometry are 
increasingly more common.  As our laboratory has utilized predominantly mass spectrometry-
based technologies for initial biomarker discovery, this method will be elaborated on below.   
Mass spectrometry (MS) is a sensitive and analytical technique used for a variety of 
applications including identification of unknown compounds and analysis of biological samples.  
All MS instruments consist of three parts:  an ion source which ionizes the sample, a mass 
analyzer which sorts ions by mass using an electromagnetic field and a detector which measures 
the time-of-flight and the abundance of each ion present.  This technique is based on the 
principle of sample desorption and ionization with subsequent detection based on mass-to-charge 
(m/z) ratios.  
Two of the ion source techniques commonly for the analysis of liquid and solid biological 
samples are matrix-assisted laser desorption/ionization (MALDI) and electrospray ionization 
(ESI).  For MALDI, samples are mixed with an energy-absorbing matrix (EAM) and applied to a 
metal plate where crystals form once dried.  Laser energy is then used to ionize the EAM which 
 33 
transfers protons to the sample and protects it from the energy of the laser [138].  Once ionized, 
the samples are desorbed from the plate and in the gas phase prior to being injected into the mass 
analyzer.  Mass analyzer technologies include time-of-flight (TOF), quadrupole (Q), ion trap and 
combinations of these (i.e., Q-TOF).  For the TOF mass analyzer, an electric field is used to 
accelerate ions through the same potential.  The time to reach the detector (or time-of-flight) is 
then measured.  Particles with the same charge (and same kinetic energy) will be identical such 
that the velocity at which they travel will depend only on their mass.  In other words, mass is 
directly proportional to the speed at which the ions travel with lighter ions reaching the detector 
first.  Ultimately, the detector records when an ion reaches a surface to produce a mass spectrum.     
A modified version of MALDI-TOF-MS is surface-enhanced laser desorption/ionization 
time-of-flight mass spectrometry (SELDI-TOF-MS).  In SELDI-TOF-MS, the solid-phase 
chromatographic surfaces are modified either chemically or biochemically to retain proteins 
according to specific properties such as hydrophobicity or charge [139, 140].  Retained proteins 
are then ionized and detected by TOF-MS and the resulting spectra displayed as peak intensities 
of various molecular masses ranging from 0-200 kilodaltons (kDa) as with MALDI-TOF-MS.  A 
key feature of these mass spectrometry-based techniques is their ability to provide a rapid protein 
expression profile from a variety of biological and clinical samples [141].  If used in combination 
with computer-based algorithms, a panel of potential biomarkers can be selected and used for 
diagnostic purposes [142].   
1.5.3 Value of Biomarkers 
In general, biomarkers could be used to accurately detect the presence of disease, provide 
mechanistic disease information, identify landmarks of disease progression, indicate the 
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effectiveness and overall response to treatment and allow for comparisons between human and 
animal models (Figure 11).  In addition, protein biomarkers could be generated to predict either 
prognostic or therapeutic outcomes and allow for customized therapeutic interventions.  With 
discovery efforts that include mass spectrometry and antibody-based arrays like the enzyme-
linked immunosorbent assay (ELISA), multiple potential clinical uses for biomarkers have been 
suggested (Figure 12). 
 
Figure 11.  Potential Uses of Biomarkers 
The progressive degeneration and subsequent loss of motor neurons that occurs with ALS begins 
with the initiation of the disease process.  As depicted in the schematic, biomarkers may be 
identified at all stages of the disease process and used for multiple purposes. 
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Figure 12.  Proteomic Biomarker Discovery Efforts for ALS 
Patient samples can be examined by a number of proteomic technologies including sodium 
dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE), mass spectrometry and array 
profiling.  These results are analyzed to uncover putative disease-specific biomarkers which are 
then validated for measures in diagnostics, toxicity or disease progression.  Protein biomarkers 
are also used to identify proteins or pathways for development as therapeutic targets. 
Significant research efforts have been made to identify biomarkers of neurodegenerative 
diseases such that earlier diagnoses and therapeutic interventions can be made.  In the case of 
ALS, inadequate diagnostic tools and disease complexity cause, on average, a 13-month interval 
between symptom onset and diagnosis [143].  Currently, the clinical diagnosis of probable ALS 
is made only when both upper and lower motor signs are present [32-34].  However, UMN 
involvement can be missed when LMN involvement is severe, thereby prolonging the pre-
diagnosis testing period and increasing a patient’s period of uncertainty regarding diagnosis.  
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More sensitive and objective diagnostic methods are indeed necessary, particularly to improve 
detection of UMN involvement. 
In the context of drug discovery, disease-specific biomarkers and/or biomarker panels 
have become an attractive option for identifying therapeutic targets for which specific agents 
could be designed.  This is of particular interest in the treatment of ALS where current drug 
treatment options are limited and impart minimal life-prolonging benefits.   
Protein biomarkers may also help define subtypes of ALS or determine which patients 
will more rapidly progress.  Specifically, the use of protein biomarkers may enable researchers to 
link specific pathogenic mechanisms to either bulbar or limb onset ALS.  In addition, proteomic 
profiling has the potential to greatly impact the field of toxicology by identifying biomarkers that 
can be used as measures of toxicity related to a particular drug or chemical.  Protein profiling to 
uncover ―safety biomarkers‖ related to drug-induced toxicity [144, 145], called toxicoproteomics 
[146], provides the opportunity to rapidly assess risk/hazard affects of new drugs or chemicals 
and could enable drug companies or academic investigators to make quick decisions with regard 
to drug development activities. 
Finally, protein biomarkers may be useful to bridge model systems and provide 
translational biomarkers to assess efficacy or toxicity in animal models [147].  This would be 
quite valuable for a neurologic disease such as ALS where current drugs successful in slowing or 
delaying disease during preclinical trials in the SOD1 transgenic mouse model for ALS have 
typically failed when tried in humans.  While it remains unclear how accurately the rodent 
models for ALS mimic the human disease, protein biomarkers common to both the rodent model 
and human disease would be quite valuable and informative in identifying key biochemical 
pathways to target for drug screens.  Drugs that modulate protein biomarkers common to animal 
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models and human ALS patients that are demonstrated to be effective in the animal model would 
have increased justification for use in human clinical trials.  The use of protein biomarkers that 
bridge the model systems may reduce the time from bench to bedside for effective treatments.  
Targeted proteomic studies that examine protein levels of specific proteins in control and disease 
states have led to the generation of ELISA-based diagnostic assays for a number of conditions.  
There are currently no validated and FDA-approved diagnostic tests using newer proteomic 
technologies like mass spectrometry, suggesting that while these technologies hold great promise 
there is still much work remaining to translate the findings to the clinic.  Other proteomic 
methodologies such as protein arrays or antibody arrays promise to uncover pathogenic 
mechanisms in neurologic diseases as well.   
1.5.4 Important Considerations in Biomarker Discovery 
Improvements in diagnosis, monitoring of disease progression and evaluation of drug efficacy or 
toxicity are needed for ALS.  Similarly, markers enabling patient stratification and treatment 
selection remain unmet medical needs, prompting many to turn to biomarker discovery.  
Although the proteomics field has exploded in recent years, few, if any, of the potential 
biomarkers identified have held up to subsequent validation studies.  Although unfortunate, these 
failures indicate that efforts must be made to reduce both pre-analytical and analytical variables 
as much as possible. 
Pre-analytical variables including patient health and diet, time of day, fasting, position 
during sample collection, collection tubes, temperatures, centrifugation times and temperatures, 
shipping and storage times and processing times, temperatures and conditions can all affect the 
results of proteomic analyses [148].  Therefore, strict adherence to stringent protocols is required 
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to minimize sample-to-sample variability.  Prospectively collected samples are also required as 
banked samples have most likely been collected or stored inconsistently, or their viability has 
been compromised due to long storage periods.  For instance, Carrette and colleagues found that 
cystatin C in the CSF undergoes cleavage at its amino terminus during long-term storage at         
-20
o
C but not when stored at -80
o
C [148].  As noted by these authors, this ―artifactual, storage-
related truncation‖ could erroneously be considered of biological significance if it is not 
carefully assessed prior to additional testing [148].    
Similarly, experimental design is critical in that correctly collected samples from the 
proper patient cohorts (ALS, healthy controls, neurologic disease controls including diseases 
with symptoms that mimic ALS) are utilized within a well-characterized analytical system.  
Although seemingly obvious, proper controls, matched to case samples in sufficient numbers, 
must be included to reduce chance and overfitting and to provide statistical significance.  In 
addition, there must be sufficient power within the experimental design to identify true positives 
and eliminate false positives.  Finally, randomization along with other methods can and should 
be used to further reduce bias during data analysis [149]. 
It is also critical to properly validate any putative biomarkers using a distinct patient 
cohort and multiple methodologies.  In these validation studies, patients with clinical features 
similar to those observed with the disease of interest must be included.  For example, when 
diagnosing ALS patients the biomarker must appropriately distinguish individuals with ALS 
from those with multiple sclerosis, Kennedy’s syndrome or multifocal motor neuropathy.  A 
higher level of disease specificity (>95%) may be required to warrant use or approval of the 
biomarker in the clinical setting.  As indicated in Figure 13, mass spectrometry-based diagnostics 
may be capable of such patient classification/differentiation.  CSF mass spectra between 4,500 – 
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15,000 Da are shown for individual healthy control, MS and ALS subjects.  Specific peak 
patterns are common or unique amongst each of the subject types that upon proper validation 
may lead to biomarker proteins.  It may also be necessary to combine results from proteomic, 
genomic and metabolomic studies to uncover pathways relevant to disease.  This systems 
biology approach is only beginning to be applied to various human diseases but may ultimately 
provide the best means to uncover biomarkers of pathogenic disease mechanisms. 
 
Figure 13.  Deciphering ALS from Healthy and Disease Controls by Mass Spectrometry 
Mass spectrometry of CSF isolated from healthy control (top), multiple sclerosis (MS) (middle) 
and ALS (bottom) subjects.  Representative spectra from 4500-15000 Daltons (Da) are shown.  
Boxed areas highlight differences in peak pattern and intensity observed in these patient 
populations.  Mass (m/z) peak alterations enable ALS patients to be distinguished from those 
with MS or healthy controls using various computer algorithms. 
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Finally, while many of the recent SDS-PAGE proteomic studies have pre-fractionated the 
biologic samples prior to proteomic analysis, the mass spectrometry-based proteomic studies for 
ALS have yet to pre-fractionate samples.  In turn, most of the potential protein biomarkers 
identified are abundant proteins, and the analysis of low abundance proteins that may likely yield 
the best potential for disease-specific biomarkers is hindered.  Future proteomic studies should 
focus efforts on pre-fractionated samples in order to delve more deeply into the proteome.   
Regardless of the experimental approach used to identify putative biomarkers for ALS, 
an understanding of their pathological relevance will help identify and characterize disease 
mechanisms.  Ideally, proteins that function in the initiation of disease or in early pathologic 
events will be revealed along with factors that increase disease susceptibility.  In addition, 
protein identification and characterization is necessary for the development of independent 
validation assays and ultimate regulatory approval as a diagnostic tool. 
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2.0  EVALUATION OF TRANSTHYRETIN AS A BIOMARKER OF ALS 
2.1 ABSTRACT 
Currently, objective molecular markers that allow for the diagnosis and monitoring of disease 
progression are lacking for ALS.  Our laboratory previously identified transthyretin (TTR) as a 
candidate protein biomarker for ALS and observed decreased levels of TTR in the CSF of ALS 
patients when compared with healthy and other neurological disease controls [150].  To further 
characterize the role of TTR and its utility as a biomarker, the frequency of TTR genetic 
polymorphisms and post-translational protein modifications in the ALS population were 
examined using MALDI-TOF-MS analysis of TTR obtained from the CSF of ALS and control 
subjects.  In addition, enzyme-linked immunosorbent assays (ELISA) specific for total TTR were 
used to independently measure protein levels.  Preliminary results regarding genetic 
polymorphisms combined with data from single nucleotide polymorphism (SNP) studies 
conducted by other groups indicated that genetic polymorphisms were not a factor in the ALS 
population.  However, alterations in specific post-translationally modified forms of the TTR 
protein were observed.  In particular, oxidative modifications at the sole cysteine residue were 
altered.  No significant change in TTR protein level was observed over the course of the disease 
suggesting that altered post-translational protein modifications as opposed to total protein levels 
are important.  Temperature-dependent changes to these protein modifications were observed; as 
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these modifications are critical for stabilization of the tetrameric forms of TTR, preliminary 
studies to determine the impact of these alterations on protein aggregation were performed.  My 
results indicate that post-translational modifications and high molecular weight species of TTR 
are important factors in ALS pathology with further characterization required to determine the 
biological significance of each. 
2.2 INTRODUCTION 
2.2.1 Identification of TTR 
Our laboratory used SELDI-TOF-MS to identify a panel of protein biomarkers in the CSF of 
ALS patients.  Using CSF from a total of 52 ALS and control subjects along with a machine 
learning algorithm, a panel of predictive biomarkers was created and applied to a coded set of 
CSF samples for diagnostic predictions.  Three measures were used to assess the diagnostic 
utility of this biomarker panel including:  1.) the proportion of correctly predicted ALS cases out 
of all ALS cases (sensitivity), 2.) the proportion of correctly predicted control cases out of all 
control cases (specificity) and 3.) the proportion of correctly predicted cases out of all cases 
(accuracy).  Using these parameters, analysis of the small test set provided 80% sensitivity, 
100% specificity and 91% overall accuracy in predicting ALS [150].  Importantly, the 19 protein 
mass peaks included in the panel best predicted ALS in patients near the time of symptom onset.  
Subsequent studies have focused on these putative biomarkers in an attempt to maximize the 
chance of finding proteins relevant to disease pathogenesis (as opposed to those that are simply a 
consequence of the disease process or end-stage effects).  Further characterization of the 
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biomarker peaks using peptide mass fingerprinting or direct peptide sequencing with tandem 
mass spectrometry identified transthyretin (TTR) as one of the candidate biomarkers.  TTR was 
found to be decreased in the CSF of ALS patients when compared to healthy and other 
neurological disease controls [150].  
2.2.2 Biological Functions 
TTR is a tetrameric protein composed of identical 13.7 kilodalton (kDa) subunits each 127 
amino acids long [151].  It is secreted into the CSF and plasma by epithelial cells of the choroid 
plexus and liver cells, respectively [152], but it is also expressed by neurons and motor neurons 
[153, 154].  Both the expression and synthesis of TTR are independently regulated in the blood 
and CSF [155] although TTR from the CSF is catabolized by the liver, muscle and skin 
following reabsorption by arachnoid villi [156].  While TTR comprises only a small percentage 
of plasma, it is one of the most abundant proteins in the CSF comprising 12% of the total protein 
synthesized by the choroid plexus [152, 157].   
Within the CNS, TTR is involved in many important biological processes with roles in 
regulating thyroid function and modulating immune response [153, 158].  In addition, TTR 
functions as a protein chaperone with the ability to sequester proteins and prevent amyloid 
formation by binding to proteins such as the amyloid β peptide (Aβ) [159].  TTR also regulates 
retinoic acid signaling, a pathway critical for neural development/specification and neural 
plasticity and regeneration [160, 161].  Through its interaction with retinol-binding protein 
(RBP), TTR impacts vitamin A metabolism and prevents glomerular filtration of the low-
molecular-weight RBP from the kidneys [162].  Decreased TTR protein in the CSF may directly 
impact the amount of retinol available to cells of the CNS and therefore affect signaling and 
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regenerative capacities during neurologic injury or disease.  Additional work in a transgenic 
mouse model of Alzheimer’s disease (AD) demonstrated a lack of neurodegeneration in animals 
with increased levels of the TTR transcript in the hippocampus [154] suggesting that TTR may 
also be neuroprotective although this function is not fully understood.  
2.2.3 Links to Disease 
Mutations in the TTR gene have been identified as causal for multiple pathological conditions 
including TTR-related amyloidosis (ATTR), a disorder characterized by the extracellular 
systemic deposition of mutated or wild-type TTR as amyloid fibrils [163, 164].  Similarly, 
genetic variants of the TTR gene have been shown to induce familial amyloidosis in both cardiac 
and neural tissues [165, 166].  In these amyloidoses, pathological deposits composed of TTR β-
structured fibrils accumulate and cause organ dysfunction and death [167].  Recently, the 
formation of these TTR fibrils was correlated both in vitro and in a cell culture system to the loss 
of TTR quaternary structure [168, 169], suggesting that tetramer disassembly may promote 
protein aggregation and subsequent fibril formation [170]. 
2.2.4 Post-translational Protein Modifications 
Various post-translational protein modifications of TTR are known including sulfation, 
glutathionylation, phosphorylation, cysteinylation and cysteinylglycine addition.  Covalent 
adducts of TTR with sulfite (TTR-SO3H), cysteine (TTR-Cys), cysteinylglycine (TTR-CysGly) 
or glutathione (TTR-Glutathione) involve the thiol group of the sole cysteine residue of TTR 
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(Cys
10
) and are oxidative post-translational modifications of TTR [171, 172].  This cysteine 
residue plays a key role in the stabilization of the tetrameric form of TTR [173].   
In the generally accepted model of TTR fibrillogenesis, tetrameric TTR dissociates into 
monomers which in turn undergo subtle conformational changes that lead to protein aggregation, 
fibril formation and cytotoxicity [170, 174].  Therefore, altered post-translational modifications 
at the Cys
10
 residue would be expected to compromise the function of TTR.  This has been 
observed in familial amyloid polyneuropathy (FAP) where the level of Cys adducts with the 
mutant TTR chain was significantly higher in the plasma of symptomatic patients when 
compared to the wild-type protein [171].  In patients with AD, oxidized forms of TTR (i.e., TTR-
Cys and TTR-CysGly) were significantly less abundant [156].  Differential modification at this 
residue has also been shown to alter the ability of TTR to prevent Aβ aggregation and toxicity in 
mouse models of AD [175]. 
2.2.5 Study Objectives 
The goals of this study were to determine if individuals with ALS have a higher incidence of 
TTR genetic variants that alter protein function and thus constitute a novel susceptibility factor 
for the disease.  Concurrently, differential post-translational protein modifications of TTR were 
also investigated in the ALS population.  Importantly, previous studies by other laboratories have 
successfully utilized mass spectrometry to identify genetic polymorphisms in the TTR gene [176, 
177] and to investigate differential post-translational modifications of the protein [156, 178].   
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2.3 MATERIALS AND METHODS 
2.3.1 Collection and Storage of Cerebrospinal Fluid 
Patient samples were obtained from the ALS/Multidisciplinary and Muscular Dystrophy 
Association Clinics at the University of Pittsburgh Medical Center (UPMC).  ALS subjects 
included in this study were clinically diagnosed using the revised El Escorial criteria [179, 180], 
and the age range for all individuals was 20-80 years old.  All subjects were evaluated using 
accepted diagnostic principles and standards.   
CSF was obtained following IRB-approved patient consent. CSF was collected through 
lumbar puncture and centrifuged immediately after collection at 1000 rpm (450g) for 5 minutes 
at 4
o
C.  Processed CSF was stored at -80
o
C until needed or as outlined in Table 4 to determine 
the effects of storage conditions.  Mass spectrometry was used to confirm the lack of blood 
contamination within each CSF sample obtained. 
2.3.2 ELISA 
Each 96-well Immulon 4HBX ELISA plate was coated with 100 L of 1:1000 capture antibody 
(rabbit anti-human TTR, Dako, Carpinteria, CA) in phosphate buffered saline (PBS) overnight at 
4
o
C.  After washing, plates were blocked using Super Block (ScyTek Laboratories, Logan, Utah) 
with 0.05% Tween-20 for 30 minutes.  After further washing, optimized dilutions of protein 
standards and CSF samples were added and allowed to bind for 1 hour with gentle shaking at 
room temperature.  The plates were then washed again and 100 L of 1:10000 detection 
antibody (horseradish peroxidase-conjugated goat anti-human TTR, EY Laboratories, Inc., San 
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Mateo, CA) in PBS with 0.1% Tween-20 was added to each well and allowed to bind for 1 hour 
with gentle shaking at room temperature.  Detection was performed with 3,3', 5,5"-
tetramethylbenzidine (TMB, Sigma, St. Louis, MO) and stopped with 0.1 M hydrochloric acid 
(HCl).  Plates were read in a Quant micro-plate reader (BioTek Instruments, Inc., Winooski, 
VT) at 450 nm. 
2.3.3 Identification of Genetic Polymorphisms 
CSF from a total of 32 different patients (27 ALS, 5 healthy controls) was used to determine the 
frequency of genetic variants.  TTR was immunoprecipitated from human CSF with rabbit anti-
human TTR antibody (Dako) overnight at 4
o
C using antibody-coated Protein A/G PLUS-
Agarose beads (Santa Cruz Biotechnology, Santa Cruz, CA).  Disulfides were reduced with 100 
mmol/L tris(2-carboxyethyl)phosphine (TCEP) for 20 minutes at 55
o
C prior to analysis with 
mass spectrometry.  TCEP treatment was used to resolve protein mass peaks and further enable 
mass shifts caused by amino acid substitutions to be identified.  Wild-type TTR appears as a 
single spectral peak, but mass differences (typically between +/- 6-40 Daltons) are observed 
when an amino acid substitution occurs as a result of a polymorphism in the TTR gene. 
2.3.4 Detection of Post-Translational Protein Modifications 
For desalting with PepClean C18 Columns (Thermo Fisher Scientific, Rockford, IL) the solid-
phase material was activated using multiple washes with acetonitrile (ACN)/water (1:1) and then 
equilibrated in buffer containing 0.5% trifluoroacetic acid (TFA)/5% ACN.  CSF samples (20 
µL) were acidified by addition of 0.5% TFA/10% ACN (20 µL) prior to loading onto the 
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column.  Columns were washed multiple times with 0.5% TFA/5% ACN with an additional spin 
at 1500g for 1 minute to ensure dryness.  Samples were eluted from the columns with 0.5% 
TFA/70% ACN.  The eluate was then dried in a Speed Vac on medium heat for approximately 
30 minutes and resuspended in 0.5% TFA/50% ACN.  Protein modifications were analyzed and 
quantified by determining the area under the curve (AUC) of spectral peaks [181] and the 
amplitude for each mass-to-charge (m/z) position [182] and the level of each post-translational 
modification compared in ALS and control subjects. 
2.3.5 MALDI-TOF-MS Analysis 
Bovine β-lactoglobulin A and bovine ubiquitin were purchased from Ciphergen and used as 
molecular mass calibrators.  Both were dissolved in 0.1% TFA in deionized water.  The MALDI 
matrix used was a saturated solution of 3,5-dimethoxy-4-hydroxy-cinnamic acid (sinapinic acid) 
purchased from Fluka in 50% ACN and 0.5% TFA.  All MALDI analyses were performed using 
a Voyager-DE PRO MALDI-TOF mass spectrometer (Applied Biosystems, Carlsbad, CA).  
Samples were irradiated with a nitrogen laser, and the ion source and flight tube evacuated by 
turbo pumps to a pressure lower than 6 x 10
-7
 mbar.  Instrument parameters were tuned to obtain 
the highest resolution and sensitivity in the mass range 12000-14000 Daltons (Da).  All spectra 
were acquired in the linear mode, and the laser power was modulated between 10 and 30% to 
obtain similar ion counts for each sample. 
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2.3.6 Immunoblotting 
CSF from ALS patients and healthy controls was analyzed on 12% gels by non-denaturing gel 
electrophoresis.  Proteins were transferred to a polyvinylidene difluoride (PVDF) membrane 
(PerkinElmer, Boston, MA) and blocked with 5% non-fat milk/Tris-buffered saline with Tween-
20 (TBST).  Blots were probed with primary antibody overnight at 4
o
C in 5% milk/TBST and 
then washed with TBST.  Goat anti-rabbit horseradish peroxidase-conjugated secondary 
antibody was added for 2-3 hours at room temperature after which blots were washed with 
TBST.  The final reaction products were visualized using enhanced chemiluminescence 
(PerkinElmer). 
2.3.7 Statistical Analysis 
Comparisons between any two groups of data were accomplished using the unpaired t test at the 
95% confidence interval.  A p value ≤ 0.05 was considered statistically significant. 
2.4 RESULTS 
2.4.1 Genetic variations can be detected via mass spectrometry 
Initially, I demonstrated the ability to reduce immunoprecipitated TTR from the CSF.  In the 
presence of TCEP, the multiple peaks associated with the modified forms of TTR were reduced 
to one predominant peak (Figure 14) indicative of free (unmodified) TTR. 
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Figure 14.  Reduction of TTR Protein Modifications with TCEP 
TTR was immunoprecipitated from a pooled CSF sample (QC-CSF) and analyzed via MALDI-
TOF-MS.  The top panel represents the mass spectral pattern without TCEP treatment while the 
bottom panel represents the mass spectral pattern following TCEP treatment for 20 min at 55
o
C. 
TCEP-reduced TTR immunoprecipitated from the CSF from ALS patients and healthy 
controls was then analyzed to determine the frequency of a ―split peak‖ pattern indicative of 
genetic variants of free TTR.  For these studies, both ALS patients and controls were analyzed 
and example spectra are provided (Figure 15).  Of the 32 CSF samples analyzed, only 4 (3 ALS, 
1 healthy control) exhibited a ―split peak‖ pattern with a corresponding mass shift of 
approximately +30 Da.  The remaining 28 CSF samples (24 ALS, 4 healthy controls) exhibited 
only one peak indicative of free TTR.  Importantly, samples from the same patient obtained at 
different points in the disease course were consistent in the presence or absence of the additional 
TTR peak.  
 51 
 
Figure 15.  TTR Spectra Following TCEP-Reduction 
TTR from the CSF of healthy controls and ALS patients was immunoprecipitated and reduced 
with TCEP prior to MALDI-TOF-MS analysis.  Resulting spectra were examined for those with 
two peaks indicating the presence of genetic variations in the TTR gene which were observed in 
both healthy controls and ALS patients. 
2.4.2 Total TTR levels do not change over the course of the disease 
To validate the decreased levels of TTR observed via mass spectrometry, ELISA specific for 
total TTR protein was performed using longitudinal CSF samples from healthy controls (n = 8) 
and ALS patients (n = 8) obtained over an approximately two-year time period (initial and two-
year time points from healthy controls; CSF from ALS subjects was collected every 4-6 months 
for the two-year time period).  Over the course of the disease, the level of total TTR did not 
change significantly for either group (Figure 16). 
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Figure 16.  Overall Levels of TTR Do Not Change Over the Course of the Disease 
Longitudinal analysis of CSF from ALS patients (n = 8) and healthy controls (n = 8) shows 
similar levels of TTR protein over time.  A representative healthy control (top line) and ALS 
patient (bottom line) are shown.  Similar results were obtained when plasma was analyzed in 
these patients. 
2.4.3 Oxidative modifications of TTR can be detected via mass spectrometry and are 
altered with different storage conditions 
We next examined TTR immunoprecipitated from human CSF to determine if altered protein 
processing occurs.  Although the spectral patterns observed in the absence of reducing agent 
indicated that protein modifications could be detected, we confirmed the presence of additional 
TTR peaks indicative of post-translational modifications in the CSF and observed alterations in 
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the pattern of these peaks when CSF from ALS patients and healthy controls was compared 
(Figure 17). 
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Figure 17.  Post-translational Modifications of TTR are Detectable via Mass Spectrometry 
MALDI-TOF-MS analysis indicates that peaks corresponding to the modified forms of TTR are 
altered in ALS patients.  Representative spectrograms from a healthy control (top) and ALS 
patient (bottom) are provided. 
 PepClean C18 columns were then utilized to remove salt from the CSF prior to MALDI-
TOF-MS analysis.  Based on initial observations, we sought to further characterize and then 
compare the post-translational protein modifications of TTR that occur in ALS patients including 
sulfation, phosphorylation, cysteinylation, cysteinylglycine addition and glutathionylation.  With 
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the exception of phosphorylation, these additions occur at the single cysteine residue and often 
comprise the majority of species found in circulation [176].  These studies indicated that these 
modified forms of the protein could be detected via mass spectrometry and that specific 
oxidative modifications were decreased in ALS patients when compared to healthy controls 
(Figure 18).  
 
Figure 18.  Oxidative Post-translational Protein Modifications are Altered in ALS Patients 
MALDI-TOF-MS analysis of CSF from a healthy control (top) and ALS subject (bottom) are 
shown.  Reduced levels of specific oxidative post-translational protein modifications (i.e., 
sulfonated and cysteinylated TTR) can be observed in patients with ALS. 
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 Subsequent analyses to quantify these differences using a much larger sample set and 
longitudinal CSF samples indicated that modified forms of TTR were altered depending on the 
temperature at which they were stored prior to analysis.  In an attempt to determine which 
modifications were reflective of fresh CSF samples, a variety of storage conditions were 
compared (outlined in Table 4) to fresh CSF and CSF snap frozen in liquid nitrogen.  The results 
of these experiments are shown in Figures 19 and 20. 
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Figure 19.  MALDI-TOF-MS of CSF Stored at Various Temperatures 
CSF samples were desalted and then analyzed via MALDI-TOF-MS to determine the effects of 
storage conditions on modified forms of the protein.  Only spectra from samples stored at -80
o
C 
initially were obtained as this is standard processing. Differences in peak patterns were 
observed when storage conditions varied.  Numbers correspond to the samples listed in Table 4. 
 
 
Figure 20.  Immunoblot Analysis of CSF Stored at Different Temperatures 
CSF samples were analyzed using non-denaturing gel electrophoresis to determine if storage 
temperature and conditions affected the high molecular weight bands immunoreactive for TTR.  
The intensity of many bands is altered.  Numbers correspond to the samples listed in Table 4 and 
“+” denotes purified TTR. 
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Table 4.  Storage Conditions Utilized to Determine the Relationship of Temperature to Protein Modifications 
Sample Number Storage Conditions Prior to Analysis 
1 Fresh (unfrozen) 
2 Snap frozen in liquid nitrogen 
3 -80
o
C only 
4 -80
o
C followed by -20
o
C for 24 hours 
5 -80
o
C followed by -20
o
C for 72 hours 
6 -80
o
C followed by a thaw at room temperature with -80
o
C storage for 4 days 
7 -80
o
C followed by a thaw at room temperature with -20
o
C storage for 4 days 
8 -20
o
C only 
9 -20
o
C followed by -80
o
C for 24 hours 
10 -20
o
C followed by -80
o
C for 72 hours 
11 -20
o
C followed by a thaw at room temperature with -20
o
C storage for 4 days 
12 -20
o
C followed by a thaw at room temperature with -80
o
C storage for 4 days 
2.4.4 High molecular weight forms of TTR are present in the CSF of ALS patients 
Finally, we sought to further characterize a TTR-immunoreactive species that did not enter the 
gel (Figure 21A) and was present in ALS samples by performing non-denaturing gel 
electrophoresis using CSF from ALS and healthy control subjects.  Our preliminary analyses 
indicate that levels of this high molecular weight TTR species are increased in ALS patients and 
that particular high molecular weight bands are present only in ALS (Figure 21B). 
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Figure 21.  Denaturing and Non-Denaturing Gel Electrophoresis for TTR 
CSF was analyzed under denaturing (A) or non-denaturing (B) conditions.  A:  TTR 
immunoreactive bands that did not enter the gel were observed.  B:  CSF from 2 ALS (lanes 1 
and 2) and 1 healthy control (lane 3) were subjected to non-denaturing gel electrophoresis and 
TTR immunoreactive species identified.  Monomeric TTR is observed around 14 kDa.  High 
molecular weight species were positive for TTR, and many of the bands corresponding to these 
protein species were more intense in the ALS patients when compared to the healthy control. 
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2.5 DISCUSSION 
Our laboratory has previously demonstrated decreased levels of TTR in the CSF of patients with 
ALS, and we sought to further characterize the potential of this protein as a biomarker of ALS.  
This study utilized mass spectrometry to distinguish between wild-type and variant forms of 
TTR and to identify oxidative post-translational modifications of the protein.  Although genetic 
variations in the TTR gene could be detected at the protein level, they did not appear to be more 
abundant in the ALS population.  However, specific oxidative post-translational protein 
modifications were altered in the ALS patient population despite the fact that the total TTR 
protein level did not change over the course of the disease as measured by ELISA.  In studies to 
further investigate these alterations, temperature-dependent changes were observed using both 
mass spectrometry and immunoblotting techniques.  In addition, preliminary studies suggest that 
high molecular weight protein species are more abundant in the CSF of patients with ALS when 
compared to healthy controls.  Additional studies are required to validate these initial findings 
and to determine if these high molecular weight TTR species contribute to extracellular or 
intracellular protein aggregation in ALS patients. 
Approximately 110 known variants of the TTR protein exist, and the pathogenic variants 
have been associated with protein plaques (amyloid) that cause organ dysfunction and death 
[183].  Although we were able to detect variant forms of TTR, my results suggest that genetic 
variants in the TTR gene do not contribute to ALS pathogenesis.  However, the mass 
spectrometry-based system used was not sensitive enough to resolve mass differences less than 6 
Daltons.  These variants could result from a single amino acid change, a double variant or a 
variant that does not circulate [184].  In addition, mass differences that are isobaric (e.g., Leu to 
Ile) would not be detected.  However, the speed with which we could perform the study 
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warranted its use as an initial screen of our ALS population.  In addition, the known TTR 
variants with mass shifts less than 10 Daltons are not common, and they constitute only 10% of 
the known variants [176].  In fact, if all potential single-amino-acid variants are examined, 48 of 
380, or 12.6%, would have a variant that is less than 10 Daltons, giving a theoretical minimum 
sensitivity of approximately 87% [176].  Nevertheless, in combination with data from single 
nucleotide polymorphism (SNP) studies covering the TTR gene performed by other groups 
[185], we are confident that this does not represent a novel susceptibility factor for this disease. 
The mass shift that we observed (+30 Da) likely corresponds to the Gly6Ser 
polymorphism which is present in the Caucasian population with a 12% prevalence [176].  
Although DNA sequence analysis was not used to confirm this observation, it has previously 
been reported that the circulating concentrations of variant forms of TTR are lower in abundance 
than those of wild-type TTR [186, 187].  The exception is the Gly6Ser variant which is usually 
present in close-to-equal abundance.  The spectral patterns observed in our analyses indicates an 
approximate equal abundance of the wild-type and variant forms of TTR suggesting that this 
common variant is present in our patient population.  
Our ELISA data confirmed that decreased TTR protein levels are present in the ALS 
population although these levels did not appear to change with disease progression.  A decrease 
in TTR could negatively affect retinoid signaling, a pathway critical during neural 
development/specification, with evidence supporting a role for this signaling pathway during 
adulthood as well.  More specifically, RA-dependent signaling cascades have been suggested to 
play an important role in the intrinsic regenerative capacity of the CNS following injury or 
degeneration [188].  As the importance of the interaction between TTR and retinol-retinol 
binding protein (retinol-RBP) is well-documented [153, 162, 189, 190], decreased levels of TTR 
 61 
could prevent or at least decrease the amount of retinol available to cells of the CNS.  In the 
context of ALS, this could translate to a diminished regenerative response in degenerating motor 
neurons attempting to promote their own survival.  Additional characterization of proteins of this 
signaling pathway is addressed in Chapter 3.  
The observation that post-translational modifications of the TTR protein are altered in the 
CSF of patients with ALS suggests that these changes may also be of great importance in disease 
pathogenesis.  As TTR is known to function as a protein chaperone with the ability to sequester 
proteins like amyloid β [191], the impact of these modifications on the formation of amyloid 
fibrils/deposits is of great interest.  It is worth noting that in transgenic mice overexpressing a 
mutant form of amyloid precursor protein, the TTR gene was found to be the most relevant 
overexpression change in a microarray screen of over 12,000 mouse genes [154].  This 
differential expression pattern was associated with activation of cell survival pathways and a lack 
of neurodegeneration [154].  This same group demonstrated reversal of this protective phenotype 
upon treatment with a TTR-neutralizing antibody [192] although it is unclear how the presence 
(or absence) of thiol adducts modulates these neuroprotective abilities.  The observation that 
altered levels of modified TTR protein are present in the ALS CSF combined with preliminary 
data on high molecular weight and TTR-immunoreactive protein species in ALS indicates that 
these two phenomena might have a common biochemical link. 
Previous studies have utilized similar methods to those employed in this study to 
investigate the differential oxidation of TTR thiols in serum [171] and CSF [156].  Interestingly, 
the percentage of conjugated (modified) TTR to unconjugated (free) TTR in these studies 
correlated with disease but the predominant form of TTR differed depending on the biofluid 
analyzed.  That is, in the serum of familiar polyneuropathy (FAP) patients, the percentage of 
 62 
conjugated to unconjugated TTR was higher in FAP symptomatic patients than in asymptomatic 
carriers [171].  However, in the CSF of patients with Alzheimer’s disease (AD), the thiol 
conjugated forms of TTR were much less abundant than observed in control patients [156].  This 
difference may be explained by the fact that serum TTR is regulated and expressed by the liver 
while CSF TTR is produced predominantly by the cells of the choroid plexus.  Therefore, it is 
possible that the post-translational protein modifications observed in the CSF depend, at least in 
part, on the redox balance of the CNS.  In fact, it has been suggested that this balance might 
determine disease progression by impacting the propensity of TTR to form fibrils [156].  If this 
is found to be the case in ALS, TTR post-translational modifications may be useful biomarkers 
for disease progression. 
The relationship between TTR levels and the nutritional status of patients with ALS is 
another consideration.  As the half-life of TTR is relatively short (approximately 2 days in the 
plasma), it is more sensitive to changes in protein-energy status and its concentration closely 
reflects recent dietary intake [193, 194].  Therefore, serum levels of TTR which normally range 
from 15.7-29.6 mg/dL are commonly used to assess the degree of malnutrition as mild (12-15 
mg/dL), moderate (8-10 mg/dL) or severe (<8 mg/dL).  As it is well-established that deficiencies 
in energy intake/malnutrition are associated with a poor prognosis in ALS patients [195, 196], 
the impact of post-translational modifications on TTR half-life could be examined further to 
determine their impact. 
The effects of pre-analytical factors on the stability of the proteome in mass 
spectrometry-based research is well-documented [197], and our laboratory has certainly 
contributed to these findings [198].  While artifactual and storage-related truncations have been 
reported previously [148], the observed temperature-dependent changes in modified forms of the 
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TTR protein are still somewhat intriguing.  For certain high molecular weight TTR-
immunoreactive bands, there appears to be a ―reversal‖ of the formation of these protein species 
when samples are moved from -20
o
C to -80
o
C (Figure 20).  Although this phenomenon cannot 
currently be explained, a recent mass spectrometry-based validation study performed in our 
laboratory using CSF from a total of 241 subjects [100 ALS, 53 Alzheimer’s disease (AD), 41 
healthy controls (HC), 18 multiple sclerosis (MS), and 29 other neurologic diseases (DC)], 
confirmed the presence of TTR-CysGly in patients with ALS.  The observed increase in this 
modified form of TTR suggests that thiol-conjugated TTR plays a role in ALS disease 
pathogenesis although further studies are necessary to understand the impact of these 
modifications and to determine whether they contribute to or occur as a result of the disease 
process.   
Intracellular and extracellular protein aggregates have been observed in ALS, and the 
contribution of TTR to these aggregates warrants further study.  As modifications of TTR at the 
Cys
10
 residue are critical for stabilization of the tetrameric (and functional) form of TTR, 
alterations or a lack thereof at this residue could lead to disassembly of the functional form of 
TTR into its monomeric components.  Further conformational changes could result in the 
formation of protein aggregates.  As we have observed both intracellular and extracellular TTR 
in the lumbar spinal cord of patients with ALS [150], we hypothesize that a variety of 
connections between TTR and ALS are plausible (outlined in Figure 22).  The exact role of TTR 
in ALS disease pathogenesis is being further investigated using a variety of techniques including 
high performance liquid chromatography (HPLC), liquid chromatography-tandem mass 
spectrometry (LC-MS/MS) and primary motor neuron cultures.  
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Figure 22.  Potential Roles of TTR in ALS 
The hypothesized potential roles of TTR in ALS pathogenesis are depicted above.  TTR forms 
extracellular aggregates (non-fibrillar and fibrillar) that impact gene expression by binding to 
receptors like the receptor for advanced glycation end products (RAGE) and modulating NF-κB-
dependent gene expression (left).  Intracellular TTR can function as a chaperone for other 
proteins thereby preventing misfolding and aggregation but under conditions of stress or injury 
the formation of TTR aggregates would be cytotoxic (middle).  TTR impacts retinoic acid 
signaling thereby affecting the expression of downstream genes containing retinoic acid 
response elements (RAREs) (right). 
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3.0  RETINOID SIGNALING ALTERATIONS IN ALS PATIENT TISSUE 
3.1 ABSTRACT 
ALS is a fatal neuromuscular disease for which effective therapeutic interventions and an 
understanding of underlying disease mechanism are lacking.  A variety of biochemical pathways 
are believed to contribute to the pathophysiology of ALS that are common to both sporadic and 
familial forms of the disease [9].  Evidence from both human and animal studies indicates that 
expression of retinoid signaling genes is altered in ALS and that deficiencies in this signaling 
pathway may contribute to motor neuron loss [199-206].  My objective was to examine the 
expression and distribution of proteins of the retinoid signaling pathway in spinal cord samples 
from patients with sporadic and familial ALS.  In sporadic ALS, the cytoplasmic binding protein 
that facilitates nuclear translocation of retinoic acid, cellular retinoic acid binding protein-II 
(CRABP-II), was localized to the nucleus and retinoic acid receptor β (RARβ) was significantly 
increased in motor neuron nuclei when compared to either familial ALS patients or non-
neurologic disease controls.  Motor neurons with increased nuclear RARβ were negative for 
markers of apoptosis.  Differences in protein-protein interactions between CRABP-II and the 
nuclear receptors were not detected; however increased binding at the retinoic acid response 
element was observed in spinal cord extracts from ALS patients.  This data suggests retinoid 
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signaling is altered in ALS and increased nuclear RARβ occurs in motor neurons of sporadic 
ALS patients. 
3.2 INTRODUCTION 
3.2.1 Overview of the Retinoid Signaling Pathway 
Within the cell, the level of free versus bound retinol and retinoic acid (RA) are regulated by 
cellular retinol-binding protein (CRBPI) and cellular retinoic acid-binding proteins (CRABP-I 
and II), respectively [207] (Figure 23).  CRBPI binds retinol in the cytoplasm and promotes its 
metabolism to retinaldehyde [208] and esterification to the retinyl ester for storage [209].  
CRABP-I has been suggested to promote the catabolism of RA [210] whereas CRABP-II is 
thought to mediate the transport of RA to the nucleus for association with its receptors [211].  
RA mediates its effects on gene transcription through the retinoic acid receptors (RARs) and the 
retinoid X receptors (RXRs) [212, 213].  Each receptor has three isotypes (α , β and γ) with 
multiple isoforms of each subtype generated by alternative splicing and differential promoter 
usage [212].  RARs are activated by either all-trans retinoic acid (ATRA) or 9-cis-retinoic acid 
(9-cis-RA) and mediate gene expression by forming heterodimers with RXRs whereas RXRs are 
activated only by 9-cis-RA and modulate gene expression either as homodimers or by forming 
heterodimers with RARs or a variety of orphan receptors such as peroxisome proliferator-
activated receptor (PPAR), nerve growth factor receptor-induced orphan receptor (NGFI-B) and 
thyroid hormone receptor [214-216]. 
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These retinoic acid nuclear receptors function as ligand-activated transcription factors 
and allow retinoic acid to serve as a transcriptional activator for a large number of other, 
downstream regulatory molecules including enzymes, transcription factors, cytokines and 
cytokine receptors [161].  Although less studied, retinoic acid receptors can also function as 
transcriptional repressors.  That is, in the absence of ligand, receptors remain bound to the 
response element within the gene promoter where they can act as strong inhibitors of gene 
transcription [161].  In addition, RA has been shown to impact phosphatidylinositol-3-kinase 
(PI3K) and extracellular signal-regulated kinase 1/2 (ERK1/2) mitogen-activated protein kinase 
(MAPK) signaling pathways through a rapid, non-genomic mechanism [217-221].  Finally, 
interactions between mitochondria and both cytoplasmic binding proteins and nuclear receptors 
of the retinoic acid signaling pathway indicate a role for this signaling molecule in mitochondrial 
function [222-224]. 
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Figure 23.  Retinoid Signaling Overview 
Retinol is transported throughout the body in complex with transthyretin (TTR) and retinol 
binding protein (RBP).  At the cell surface, receptors such as STRA6 transport retinol into the 
cell where it is converted to all-trans RA and 9-cis RA through the action of dehydrogenases 
(including RALDH2).  Interactions with cytoplasmic binding proteins (CRBPI, CRABP-I and 
CRABP-II) determine downstream fate.  CRABP-II facilitates interactions with the nuclear 
receptors (RARs and RXRs) which function as ligand-activation transcription factors that 
modulate target gene expression via binding at retinoic acid response elements. 
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3.2.2 Role in CNS Development 
RA is a member of the retinoid family of lipids and mediator of vitamin A activity.  It is an 
essential morphogen in vertebrate development and is critical for neural 
development/specification and neural plasticity and regeneration [160, 161].  During neural 
development, RA is thought to act after neural induction by noggin, follistatin and chordin [225].  
RA, along with fibroblast growth factors (FGFs) and Wnts, simultaneously induce neurogenesis 
and create the anteroposterior (AP) pattern of the CNS.  For AP patterning, RA up-regulates a 
variety of posterior genes (Krox20, Wnt1, En, Pax2, XIF-3, Xlim-1 and Hox genes) while down-
regulating anterior genes (Otx2, XCG-1, XAG-1, XA-1, Emx1, Emx2, Dlx1 and XINK-2).  This 
generates pattern in the posterior hindbrain and anterior spinal cord [225].  A similar role for RA 
occurs during neurogenesis in that it up-regulates some (X-ngnr-1, X-MyT1, X-delta-1 and N-
tubulin) and down-regulates other (Zic2 and X-shh) identified genes. 
 During spinal cord development, RA is required at multiple times for a series of inductive 
events (outlined in Figure 24).  First, it acts as a posteriorizing factor during neuronal induction 
along with Wnts and FGFs to pattern the anterior spinal cord.  It is then required for the 
induction of a subset of ventral interneurons known as V0 and V1 which are characterized by the 
expression of Dbx1, Dbx2 and En1 proteins.  The induction of neural differentiation throughout 
the spinal cord via the gene NeuroM also requires RA.  Then, in combination with sonic 
hedgehog (Shh), RA initiates motor neuron differentiation via the gene Olig2 for the production 
of lateral motor column (LMC) neurons which innervate limb muscles.  For each of these events, 
RA synthesized in the adjacent mesoderm/somites diffuses into the overlapping neural 
plate/neural tube in a paracrine fashion [226].  Later stages of motor neuron differentiation 
involve the migration of a subset of later-born motor neurons through a RA signaling region 
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consisting of earlier-born LMCs to differentiate into the lateral part of the lateral motor column 
(LMCL).  This highlights the crucial role of RA signaling in development of the motor neuron 
complement as well as the inductive nature of RA in spinal cord development, neuronal 
differentiation and patterning. 
   
Figure 24.  Retinoic Acid in Interneuron and Motor Neuron Development 
The gene pathways involved in the production of V0 and V1 interneurons and motor neurons as 
well as the points of action of RA (retinoic acid) are outlined.  After Shh (sonic hedgehog) from 
the floor plate has established the general conditions for motor neuron differentiation, RA 
signaling from the somites initiates further differentiation steps.  Figure taken from [226]. 
3.2.3 Roles in Adulthood 
Experimental evidence indicating that vitamin A-mediated signaling continues to play a role in 
adulthood comes from studies in animal models of vitamin A deprivation [206, 227] with 
additional studies suggesting that retinoid signaling can promote regeneration of the adult rodent 
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nervous system [228-230] or impact the process of neurodegeneration [231, 232].  Interestingly, 
retinoid-sensitive sequences have been described in the regulatory regions of over 500 genes, 
some of which have a neuronal expression pattern and encode for enzymes involved in the 
biosynthesis and degradation of neurotransmitters, ligand-gated ion channels, G protein-coupled 
receptors, neurotransmitter transporters, voltage-gated ion channels, cytoskeletal proteins and 
intracellular signaling molecules [233].  RA-mediated gene expression has also been detected in 
different cell types throughout the adult neuraxis (including the spinal cord) [234-237] with an 
up-regulation of molecular factors involved in RA-mediated responses following injury or 
degeneration in the adult CNS (outlined in Figure 25).  This suggests that RA-dependent 
signaling cascades could play an important role in the intrinsic regenerative capacity of the CNS. 
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Figure 25.  RA-Mediated Responses Associated with Injury or Degeneration in the Adult CNS 
In response to CNS injury or degeneration, a number of RA-related responses are altered.  The 
arrows indicate the main anatomic location where the changes have been described with the 
condition/pathology in green.  The figure is color-coded to denote brain hemispheres (yellow), 
cerebellum (orange), brainstem and spinal cord (blue) and subcortical structures (red).  Figure 
taken from [188]. 
3.2.4 Connections to ALS 
RA has been shown to increase peroxisome proliferator-activity binding to the peroxisome 
proliferator-response element that participates in the induction of the rat SOD1 gene [238] and to 
reduce susceptibility to oxidative stress in chick embryonic neurons [239, 240], PC12 cells [241] 
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and mesangial cells [242] although the mechanism for this antioxidant effect remains unclear.  
Similarly, Ahlemeyer and colleagues found that treatment with RA prevented staurosporine-
induced decreases in SOD1 and SOD2 protein levels and reduced oxidative stress and apoptotic 
damage in primary cultures from neonatal rat hippocampus [243].  Taken together, these studies 
suggest that RA may improve the antioxidant defense system and that deficiencies may 
exacerbate or cause cell damage/death. 
In addition to the observation that RA can modulate SOD1 gene expression, multiple 
studies have demonstrated that genes for retinoid pathway proteins and genes regulated by 
retinoid signaling are differentially expressed in post-mortem tissues from ALS patients [199-
203].  Moreover, in transgenic animal models of familial ALS, spinal cord gene expression 
profiling has revealed altered expression of genes of the retinoid signaling pathway [204].  A 
recent study using the mutant G93A SOD1 transgenic rat model of ALS indicates that changes in 
the retinoid receptor expression profile occur in the spinal cord of early pre-symptomatic and 
terminal stage disease both at the RNA and protein levels [205].  Furthermore, Corcoran and 
colleagues observed astrocytosis, accumulation of neurofilaments and motor neuron loss in the 
lumbar spinal cord of vitamin A deficient animals [206].  Finally, single nucleotide 
polymorphisms in the anaplastic lymphoma kinase (ALK) gene are correlated to sporadic ALS 
[244].  As ALK is modulated by midkine (a heparin-binding growth factor with putative 
functions in neurogenesis, neurodifferentiation and cell survival) through 9-cis-RA and the 
RXRs, this serves as additional evidence suggesting a role for polymorphisms in genes 
modulated by the retinoid receptors in ALS.  However, as a systemic vitamin A deficiency has 
not been observed in patients with ALS [245], it remains unclear how this signaling pathway 
plays a role in the disease process. 
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3.2.5 Study Objectives 
The goal of this study was to investigate the role of proteins involved in the RA signaling 
pathway in ALS.  My overall hypothesis was that retinoid signaling is altered in ALS and 
thereby contributes to motor neuron cell death.  I analyzed post-mortem lumbar spinal cord 
tissue from individuals with both sporadic and familial ALS and non-neurologic disease controls 
to determine the levels and subcellular localization of proteins involved in this pathway.  
Specific protein-protein interactions were examined as well as protein-DNA interactions. 
3.3 MATERIALS AND METHODS 
3.3.1 Subjects 
Lumbar spinal cord tissue was obtained from the ALS Tissue Bank at the University of 
Pittsburgh Medical Center (RB, Director).  Approval was obtained from the University of 
Pittsburgh Institutional Review Board.  In selecting cases for this study, efforts were made to 
control for age, gender and post-mortem interval with cases with available frozen spinal cord 
tissue whenever possible.  Sporadic ALS subjects (n = 20) included in this study were clinically 
diagnosed using the revised El Escorial criteria.  Familial ALS patients (n = 4) had a family 
history of ALS.  Control subjects (n = 9) lacked clinical or neuropathological evidence of 
neurologic disease.  The age range for all individuals was 40-95 years old.  The average age at 
death was 60.25 ± 12.66 years for sporadic ALS (range, 40 to 82 years) and was not significantly 
different from familial ALS (52.75 ± 8.02 years; range, 45 to 63 years; p = 0.27) or control 
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subjects (64.78 ± 15.60 years; range, 51 to 95 years; p = 0.41).  The average post-mortem 
interval time for sporadic ALS subjects was 5.50 ± 2.12 hours (range, 2 to 11 hours) and not 
significantly different from familial ALS (6.50 ± 5.07 hours; range 3 to 14 hours; p = 0.51) or 
control subjects (7.89 ± 5.71 hours; range 2 to 20 hours; p = 0.11). 
3.3.2 Antibodies 
Monoclonal antibodies were used to detect CRBPI (G4E4; Santa Cruz Biotechnology, Santa 
Cruz, CA), CRABP-I (C-1; Novus Biologicals, Littleton, CO), RARα (763; Chemicon 
International, Temecula, CA) and RARγ (1371; Chemicon International).  Polyclonal antibodies 
were used to detect CRABP-II (K-13; Santa Cruz Biotechnology), RARβ (Chemicon 
International), cleaved caspase-3 (Asp175; Cell Signaling Technology, Boston, MA) and TDP-
43 (BC001487; ProteinTech Group, Chicago, IL).  For immunohistochemistry, these antibodies 
were used at dilutions of 1:50 (RARα and RARβ), 1:100 (CRABP-I, RARγ and cleaved caspase-
3), 1:200 (TDP-43), 1:250 (CRBPI) and 1:2500 (CRABP-II).  Western blots were probed with 
the antibodies listed above at 1:500 (CRABP-II) or alternate polyclonal antibodies to detect 
RARα (C-20; Santa Cruz Biotechnology) and RARβ (C-19; Santa Cruz Biotechnology) used at a 
dilution of 1:500. 
3.3.3 Tissue Homogenates and Protein Extraction 
Lumbar spinal cord tissue homogenates were prepared from a subset of patients (9 sporadic 
ALS; 4 familial ALS; 5 control) for co-immunoprecipitation and DNA-binding studies.  The age 
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range and post-mortem interval for this patient subgroup did not differ from that of all subjects 
nor across the subgroups. 
Spinal cord frozen tissue samples from control and both sporadic and familial ALS cases 
were homogenized and analyzed as previously described [246].  For total cell lysates, spinal cord 
tissue samples were homogenized using an Omni Tissue Homogenizer (Omni International, 
Marietta, GA) set at 15,000 rpm for 45 seconds in lysis buffer containing 25 mmol/L HEPES 
(pH 7.4), 50 mmol/L NaCl, protease inhibitor cocktail II (Sigma, St. Louis, MO) and 1% Triton 
X-100.  The homogenized product was spun at 14,000 rpm at 4
o
C and the supernatant saved as 
the total cell lysate.  Nuclear and post-nuclear extracts were prepared as described previously 
[247].  Following homogenization with a Potter-Elvehjem grinder (Omni International) in buffer 
containing 10 mmol/L Tris (pH 8.0), 10 mmol/L MgCl2, 15 mmol/L NaCl, 0.5 mmol/L 
phenylmethyl sulfonyl fluoride (PMSF), 2 μg/mL pepstatin A and 1 μg/mL leupeptin, nuclei 
were collected via low-speed centrifugation at 800g for 5 minutes.  The resulting supernatant 
was saved as the post-nuclear extract and the nuclei further extracted with high-salt buffer (20% 
glycerol, 20 mmol/L HEPES (pH 7.9), 0.42 mol/L NaCl, 0.1% Nonidet P-40, 0.5 mmol/L PMSF, 
2 μg/mL pepstatin A and 1 μg/mL leupeptin) on ice for 10 minutes.  Remaining insoluble 
material was removed via centrifugation at 14,000 rpm for 5 minutes.  The resulting supernatant 
fraction was collected as the nuclear-enriched fraction.  Protein concentrations were determined 
using the Pierce BCA Protein Assay Kit (Thermo Fisher Scientific, Rockford, IL) per the 
manufacturer’s instructions. 
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3.3.4 Immunohistochemistry and TUNEL staining 
Paraffin-embedded tissue sections (8 μM) were deparaffinized and a hydrogen 
peroxide/methanol mixture used to block endogenous peroxidase activity.  Sections were 
steamed for 20 minutes in Antigen Retrieval Citra (pH 6.0) (BioGenex, San Ramon, CA) or 
Target Retrieval Solution (pH 9.0) (Dako North America, Carpinteria, CA).  After washing, 
blocking was performed with Protein Blocking Agent (Thermo Fisher Scientific) or Power Block 
Universal Blocking Reagent (BioGenex, San Ramon, CA).  Primary antibodies were diluted in 
phosphate-buffered saline (PBS) or Super Block (ScyTek Laboratories, Logan, Utah) and 
incubated for 1 hour at room temperature in a humidified chamber.  After washing, sections were 
incubated with the appropriate biotinylated secondary antibody (1:200 dilution; Vector 
Laboratories, Burlingame, CA) for 30 minutes at room temperature in a humidified chamber.  
The signal was amplified using Vectastain ABC Reagent (Vector Laboratories) according to the 
manufacturer’s protocol.  NovaRED (Vector Laboratories) served as the chromagen and all 
sections were counterstained with hematoxylin. 
For terminal deoxynucleotidyl transferase (TdT)-mediated dUTP-biotin nick end-labeling 
(TUNEL), sections (4 μM) were deparaffinized, treated with proteinase K and endogenous 
peroxidase activity blocked with a hydrogen peroxide/methanol mixture.  TdT enzyme was then 
added for 25 minutes at 37
o
C.  Anti-digoxigenin conjugate (rhodamin) was added for 30 minutes 
at room temperature.  After washing, sections were incubated in 3,3'-diaminobenzidine (DAB) 
solution and counterstained with hematoxylin. 
Motor neurons located within the ventral horn of the spinal cord were counted for each 
case.  The number of motor neurons with nuclear CRABP-II or RARβ was reported as a 
percentage of the total number of motor neurons counted for each case (Table 5) and by grouping 
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(i.e., control, sporadic ALS or familial ALS).  Only motor neurons for which the nucleus could 
be observed were counted.  One slide was counted for each case although consistent staining 
patterns were observed over multiple slides.    
3.3.5 Protein-Protein Interactions 
Co-immunoprecipitation (co-IP) of nuclear-enriched fractions was performed using the 
MultiMACS Protein A/G Kit and μMACS Protein A/G MicroBeads (Miltenyi Biotech, Inc., 
Auburn, CA).  Lysates were incubated with primary antibody for two hours at 4
o
C with gentle 
rocking.  Protein A/G MicroBeads were then added to the immune complex.  After washing, 
extracts were added and the magnetically labeled protein retained on the column.  The eluted 
immunoprecipitates were analyzed by immunoblot as described below. 
3.3.6 Immunoblot 
Co-immunoprecipitated nuclear-enriched fractions were fractionated on 12% gels by sodium 
dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE).  Proteins were transferred to a 
polyvinylidene difluoride (PVDF) membrane (PerkinElmer, Boston, MA) and blocked with 5% 
non-fat milk/Tris-buffered saline with Tween-20 (TBST).  Blots were probed with primary 
antibody overnight at 4
o
C in 5% milk/TBST and then washed with TBST.  Horseradish 
peroxidase-conjugated secondary antibodies specific for each primary antibody were added for 
2-3 hours at room temperature after which blots were washed with TBST.  The final reaction 
products were visualized using enhanced chemiluminescence (PerkinElmer) and the density of 
bands measured using NIH ImageJ software (National Institutes of Health). 
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3.3.7 Electrophoretic Mobility Shift Assay 
Nuclear-enriched fractions from human lumbar spinal cord samples were prepared as described 
above.  
32
P-labeled DNA probes corresponding to the binding site for the RAR receptors were 
generated by annealing templates containing the protein binding motifs to 10-nucleotide primers 
complimentary to the 5’ end of the template.  Both consensus (5’–TCG AGG GTA GGG TTC 
ACC GAA AGT TCA CTC GGG ATC C–3’) and mutant (5’–TCG AGG GTA GGG AAC ACC 
GAA AGA CTC GGG ATC C–3’) templates were used.  Overhangs were filled using Klenow in 
the presence of [α-32P]-labeled dATP and 5mM each of dCTP, dGTP, dTTP and 5-bromo-2’-
deoxyuridine-5’-triphosphate (BrdU).  Electrophoretic mobility shift assays were performed as 
previously described [248].  Briefly, 
32
P-labeled probes were combined with 50-100 mM KCl, 5 
mM dithiothreitol, 0.25 mg/mL bovine serum albumin, 1 μg of poly (dI-dC), 20 mM HEPES (pH 
7.9), 20% glycerol and 0.2 mM EDTA.  For competition assays, unlabeled consensus or mutant 
probes were added and the binding reactions incubated for 10 minutes at room temperature.  
Protein-DNA complexes were subsequently resolved via 8% polyacrylamide gel electrophoresis 
under non-denaturing conditions in a Tris borate/EDTA buffer.  The gels were dried and exposed 
to Classic X-Ray Film, Blue Sensitive (Laboratory Products Sales, Rochester, NY) at -80
o
C for 
between 1 hour to 1 week. 
3.3.8 Statistical Methods 
Comparisons between any two groups of data were accomplished using the unpaired t test at the 
95% confidence interval.  Multi-group comparisons (sporadic ALS vs. familial ALS vs. controls) 
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were performed using ANOVA followed by the Tukey post test.  A p value ≤ 0.05 was 
considered statistically significant. 
 
Table 5.  Cases Utilized for the Human Tissue-Based Study 
 Age  Gender PMI 
(hours) 
Percentage of Motor 
Neurons with Nuclear 
CRABP-II Localization 
Percentage of Motor 
Neurons with Increased 
RARβ Nuclear Localization 
SALS1 45 M 11 40% (4 of 10) 55% (6 of 11) 
SALS2 51 M 7 50% (4 of 8) 60% (6 of 10) 
SALS3 45 M 7 82% (9 of 11) 64% (7 of 11) 
SALS4 62 M 7 70% (7 of 10) 14% (1 of 7) 
SALS5 73 M 6 82% (9 of 11) 55% (6 of 11) 
SALS6 80 F 4 64% (9 of 14) 88% (22 of 25) 
SALS7 82 M 5 64% (9 of 14) 73% (22 of 30) 
SALS8 72 F 9 50% (4 of 8) 70% (7 of 10) 
SALS9 56 M 3 63% (5 of 8) 62% (8 of 13) 
SALS10 63 F 5 67% (6 of 9) 18% (2 of 11) 
SALS11 59 M 4 67% (8 of 12) 33% (5 of 15) 
SALS12 43 M 6 70% (7 of 10) 86% (6 of 7) 
SALS13 67 M 4 41% (7 of 17) 13% (2 of 16) 
SALS14 51 M 4 78% (7 of 9) 58% (7 of 12) 
SALS15 40 M 6 38% (3 of 8) 44% (4 of 9) 
SALS16 77 F 4 89% (8 of 9) 50% (5 of 10) 
SALS17 69 M 5 80% (8 of 10) 56% (5 of 9) 
SALS18 60 F 2 70% (7 of 10) 27% (3 of 11) 
SALS19 50 F 7 88% (7 of 8) 73% (8 of 11) 
SALS20 60 F 4 78% (7 of 9) 50% (5 of 10) 
FALS1 45 M 3 17% (2 of 12) 8% (1 of 12) 
FALS2 48 F 5 17% (2 of 12) 20% (2 of 10) 
FALS3 55 M 14 56% (5 of 9) 20% (2 of 10) 
FALS4 63 F 4 50% (4 of 8) 20% (2 of 10) 
CON1 54 M 6 26% (6 of 23) 13% (2 of 15) 
CON2 51 F 5 38% (3 of 8) 18% (2 of 11) 
CON3 76 M 13 31% (4 of 13) 29% (9 of 31) 
CON4 57 M 2 25% (3 of 12) 4% (2 of 47) 
CON5 58 F 5 73% (8 of 11) 25% (6 of 24) 
CON6 82 F 5 11% (1 of 9) 19% (4 of 21) 
CON7 57 F 11 ND* 21% (7 of 34) 
CON8 95 M 20 50% (5 of 10) 0% (0 of 7) 
CON9 53 F 4 20% (2 of 10) 6% (1 of 16) 
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The age and post-mortem interval (PMI) in hours (average SALS 5.50 hours; average FALS 6.5 
hours; average control 7.89 hours) are indicated for the SALS (60.25 years), FALS (52.75 years) 
and control (64.78 years) cases.  17 of 20 SALS cases exhibited increased nuclear localization of 
RARβ as compared to controls and FALS.  *ND = not determined 
3.4 RESULTS 
3.4.1 Subcellular distribution of CRABP-II is altered in sporadic ALS spinal cord motor 
neurons 
I first examined the localization of cytoplasmic retinol and RA binding proteins in the lumbar 
spinal cord of ALS and control subjects using commercially available antibodies.  CRBPI, the 
cytoplasmic protein that mediates metabolism and storage, was not detected in spinal cord motor 
neurons of sporadic ALS, familial ALS or control subjects (Figure 26A, A-C).  CRABP-I was 
noted in all three subject groups although the immunostaining pattern and intensity were not 
significantly different across all subject groups (Figure 26A, D-F).  However, CRABP-II, the 
protein responsible for mediating nuclear translocation and facilitating nuclear receptor 
interactions, exhibited enhanced nuclear and peri-nuclear immunoreactivity in spinal cord motor 
neurons of sporadic ALS cases (Figure 26A, H).  CRABP-II was observed in a more diffuse, 
cytoplasmic pattern in both familial ALS and control subjects (Figure 26A, G and I).  When 
morphologically distinct motor neurons from multiple lumbar spinal cord sections of the 
sporadic and familial ALS and control cases were counted, the percentage of motor neurons with 
nuclear staining for CRABP-II summed across cases was 66% (135 of 205) for sporadic ALS 
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cases, 32% (13 of 41) for familial ALS cases and 33% (32 of 96) for control cases.  These 
differences were statistically significant between and across all subject groups (Figure 26B).  The 
percentage of motor neurons with punctate nuclear CRABP-II for each individual subject is 
shown in Table 5. 
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Figure 26.  Immunohistochemistry Analysis of Cytoplasmic Binding Proteins in Human Spinal Cord Tissue 
A:  Lumbar spinal cord sections were immunostained for CRBPI (A-C), CRABP-I (D-F) and 
CRABP-II (G-I) in red and counterstained with hematoxylin.  Insets represent a high power 
magnification of each panel.  Original magnifications:  200X (A to I); 400X (insets in A to I).  
B:  The localization of CRABP-II was assessed for morphologically distinct motor neurons from 
each patient group.  The percent of motor neurons with nuclear CRABP-II was significantly 
greater in patients with sporadic ALS (white bars) as compared to familial ALS (black bars; p < 
0.01) or controls (stippled bars; p < 0.001).  There was no significant difference between 
familial ALS patients and controls (p > 0.05). 
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3.4.2 RARβ immunoreactivity is significantly increased in motor neuron nuclei of 
sporadic ALS patients and does not correlate with TUNEL, activated caspase-3 or TDP-43 
staining 
I next examined the levels and localization of the three retinoic acid receptor (RAR) isotypes 
(RARα, RARβ and RARγ) in lumbar spinal cord motor neurons as these receptors are activated 
by the predominant RA isoform, all-trans RA.  RARα was observed in motor neurons of all ALS 
cases as well as controls and was localized predominantly to the cytoplasmic compartment 
(Figure 27A, A-C).  The level of this protein did not differ significantly between motor neurons 
of the three patient groups but was noted in distal processes of motor neurons of sporadic ALS 
and, to a lesser extent, control subjects.  For RARβ, there was a significant increase in the 
immunostaining of motor neuron nuclei in sporadic ALS subjects (Figure 27A, E).  In familial 
ALS and non-neurologic disease controls, RARβ exhibited a predominantly cytoplasmic 
distribution in lumbar spinal cord motor neurons (Figure 27A, D and F).  The percentage of 
motor neurons with nuclear RARβ immunostaining summed across cases was 55% (137 of 249) 
for sporadic ALS cases, 17% (7 of 42) for familial ALS cases and 16% (33 of 206) for control 
cases (Figure 27B).  This difference in nuclear RARβ was statistically significant when motor 
neurons from sporadic ALS patients were compared to those of familial ALS patients (p < 0.01) 
and controls (p < 0.001) (Figure 27B).  The percentage of motor neurons with increased nuclear 
RARβ per subject is shown in Table 5.  RARγ was not detected in spinal cord motor neurons of 
sporadic ALS, familial ALS or control subjects (Figure 27A, G-I).  
 RARβ has been implicated in molecular mechanisms regulating cell death in multiple cell 
types [249-251].  Conversely, this RAR isotype has been shown to mediate both neurotrophic 
and neuritogenic effects of retinoic acid [252].  To determine whether this response was 
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apoptotic or pro-survival, I used immunohistochemistry to evaluate the co-localization of 
TUNEL with RARβ in motor neurons.  Serial sections of lumbar spinal cord from sporadic ALS 
patients were immunostained for RARβ and TUNEL, and the same motor neurons evaluated 
from both sections as denoted by tissue landmarks.  I did not observe TUNEL staining in motor 
neurons with RARβ nuclear localization (Figure 28A) but did observe TUNEL-positive nuclei in 
motor neurons lacking nuclear RARβ (representative image in Figure 28B).  Approximately 79% 
(26 of 33) of motor neurons with nuclear RARβ immunostaining were TUNEL negative across 
multiple sporadic ALS subjects (21% (7 of 33) were both RARβ and TUNEL positive).  Similar 
results were obtained when activated caspase-3 was used as a marker of apoptosis (Figure 29).  
In addition, this RARβ nuclear localization did not correlate with cytoplasmic inclusions of 43 
kDa TAR DNA-binding protein (TDP-43) (Figure 30). 
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Figure 27.  Immunohistochemistry Analysis of RAR Proteins in Human Spinal Cord Tissue 
A:  Lumbar spinal cord sections were immunostained for RARα (A-C), RARβ (D-F) and RARγ 
(G-I) in red and counterstained with hematoxylin.  Insets represent a high power magnification 
of each panel.  Original magnifications:  200X (A to I); 400X (insets in A to I).  B:  Nuclear 
RARβ immunoreactivity was determined by counting morphologically distinct motor neurons 
from all three patient groups.  The percent of motor neurons with increased nuclear RARβ was 
significantly greater in patients with sporadic ALS (white bars) when compared to familial ALS 
(black bars; p < 0.01) or controls (stippled bars; p < 0.001).  There was no significant 
difference between familial ALS patients and controls (p > 0.05). 
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Figure 28.  Immunohistochemical Analysis of RARβ and TUNEL in Human Spinal Cord 
Serial lumbar spinal cord sections from sporadic ALS cases were immunostained for RARβ and 
TUNEL and representative cases are shown.  Identical motor neurons were imaged as 
determined by anatomical hallmarks and location within the ventral horn.  A:  Motor neurons 
with nuclear RARβ immunostaining (A) lacked TUNEL staining (B).  B:  Motor neurons within 
the spinal cord without nuclear RARβ immunostaining (A) were TUNEL positive (B).  Insets 
represent a high power magnification of each panel.  Original magnifications:  200X; 400X 
(insets). 
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Figure 29.  Immunohistochemical Analysis of RARβ and Activated Caspase-3 in Human Spinal Cord 
Serial lumbar spinal cord sections from sporadic ALS cases were immunostained for RARβ and 
activated caspase-3 and representative images are shown.  Identical motor neurons were imaged 
as determined by anatomical hallmarks and location within the ventral horn.  Motor neurons 
with nuclear RARβ immunostaining (A) lacked activated caspase-3 staining (B).  Insets 
represent a high power magnification of each panel.  Original magnifications:  200X; 400X 
(insets). 
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Figure 30.  Immunohistochemical Analysis of RARβ and TDP-43 in Human Spinal Cord 
Serial lumbar spinal cord sections from sporadic ALS cases were immunostained for RARβ and 
TDP-43 and representative cases are shown.  Identical motor neurons were imaged as 
determined by anatomical hallmarks and location within the ventral horn.  A:  Motor neurons 
that lacked nuclear RARβ immunostaining (A) were positive for nuclear TDP-43 (B).  B:  Motor 
neurons within the spinal cord with nuclear RARβ immunostaining (A) also had nuclear TDP-43 
immunostaining (B).  Insets represent a high power magnification of each panel.  Original 
magnifications:  200X; 400X (insets). 
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3.4.3 Protein interactions between CRABP-II and the nuclear receptors do not differ 
between ALS and control groups 
I next investigated interactions between cytoplasmic components of this signaling pathway and 
the nuclear receptors in lumbar spinal cord tissue.  More specifically, I examined protein-protein 
interactions between CRABP-II and either RARα or RARβ to determine the functional 
consequences of CRABP-II localization to the nucleus in ALS.  I immunoprecipitated CRABP-II 
from nuclear-enriched fractions and determined whether the nuclear receptors co-
immunoprecipitated with CRABP-II.  I observed an interaction between CRABP-II and both 
RARα (Figure 31A) and RARβ (Figure 31B) although there was no significant difference 
between ALS and control groups (Figure 31C; p = 0.9042 for RARα in ALS versus controls; p = 
0.8881 for RARβ in ALS versus controls). 
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Figure 31.  Protein-Protein Interactions in Nuclear-Enriched Fractions from Human Lumbar Spinal Cord 
Protein extracts from ALS and controls were prepared as described in the Materials and 
Methods.  Protein (500 μg) from each extract was immunoprecipitated with CRABP-II and 
resulting blots were probed with antibodies specific to RARα (A) or RARβ (B).  A:  Immunoblots 
of nuclear-enriched fractions from lumbar spinal cord co-immunoprecipitated with CRABP-II 
and probed for RARα.  B:  Immunoblots of nuclear-enriched fractions from lumbar spinal cord 
co-immunoprecipitated with CRABP-II and probed for RARβ.  C:  Graph representing the 
results from densitometry quantification.  Receptor levels were normalized to that of CRABP-II 
for each sample.  Black bars represent control cases (n = 2) and checkered bars are ALS cases 
(n = 6).  Statistical analyses were performed using an unpaired t-test with a 95% confidence 
interval.  The p values for RARα and RARβ were 0.9042 and 0.8881, respectively.  Letters and 
numbers correspond to patients in Table 5. 
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3.4.4 Retinoic acid response element binding in spinal cord tissue homogenates is 
increased in ALS as compared to controls 
Finally, I examined the DNA-binding activity of nuclear-enriched fractions from ALS patients 
and controls as a measure of RAR functional activity.  Electrophoretic mobility shift assays 
(EMSAs) were performed using nuclear-enriched fractions from spinal cord tissue.  Nuclear 
extracts were incubated with [α-32P]-labeled probes corresponding to the consensus RAR binding 
element (RARE), and retardation in protein mobility due to DNA-protein interaction was 
visualized by autoradiography. 
 I first demonstrated that nuclear RARE binding could be detected using increasing 
amounts of spinal cord extract (Figure 32A).  Numerous bands exhibit increased intensity with 
increasing amounts of nuclear extract.  I then used competition with either unlabeled consensus 
or mutant probes to determine the specificity of the bands.  The unlabeled consensus probe but 
not the mutant oligo was able to compete specific bands (data not shown).  I next examined 
nuclear fractions from patients for RARE DNA-binding activity (Figure 32B).  Bands 
representing the protein:DNA complex indicative of binding at the RARE were absent in all of 
the control extracts analyzed (n = 5).  However, this protein:DNA complex was observed in 
approximately 77% (10 of 13) of patients with ALS (Figure 32B and data not shown).  The 
nuclear extracts from subjects that lacked this band corresponded to patients that had less than 
30% of motor neurons with increased nuclear RARβ (SALS18, SALS13 and FALS1 from Table 
5). 
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Figure 32.  RARE Binding in Spinal Cord Tissue Homogenates 
Nuclear-enriched fractions from lumbar spinal cord tissue of 9 sporadic ALS, 4 familial ALS and 
5 controls were used for EMSA.  A:  EMSA using radiolabeled RARE and increasing amounts of 
spinal cord nuclear extract.  Lane assignments:  lane 1, labeled probe only; lanes 2 to 11, 
increasing spinal cord nuclear extract (100 ng, 250 ng, 500 ng, 1 μg, 2 μg, 5 μg, 10 μg, 15 μg, 20 
μg, or 25 μg).  B:  EMSA using radiolabeled oligo and spinal cord nuclear extracts (25 μg).  
Lane assignments:  lane 1, labeled probe only; lanes 2 to 3, control cases (Con8 and Con1 from 
Table 5); lanes 4 to 6, sporadic ALS cases (SALS19, SALS12 and SALS14 from Table 5); lanes 7 
to 8, familial ALS cases (FALS3 and FALS4 from Table 5). 
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3.5 DISCUSSION 
The retinoid signaling pathway is critical for neuronal development with increasing evidence that 
it has equally important functions in adulthood.  Although gene expression studies suggest that 
the RA signaling pathway and genes regulated by this pathway are altered in ALS, the role of 
this pathway in ALS remains unclear.  The goal of the current study was to examine cytoplasmic 
binding proteins and nuclear receptors of the retinoid signaling pathway in lumbar spinal cord 
motor neurons of control and ALS patients.  Interestingly, I noted differences between sporadic 
and familial forms of ALS.  More specifically, I observed increased nuclear immunoreactivity 
for both CRABP-II and RARβ in motor neurons of sporadic ALS patients.  In sporadic ALS 
cases with increased CRABP-II in motor neuron nuclei, 85% (17 of 20) also had increased 
nuclear RARβ in motor neurons.  However, I did not detect any differences with respect to 
protein-protein interactions between CRABP-II and either of the two nuclear receptor isotypes 
detected in motor neurons (RARα or RARβ).  In terms of binding at the nuclear response 
element, I observed increased binding in ALS patients.  My data indicates that there is increased 
nuclear targeting/retention of RARβ with a functional impact on transcription.  The lack of 
RARβ nuclear immunostaining in familial ALS suggests differences in underlying disease 
mechanism between familial and sporadic forms of the disease.  However, further studies are 
necessary to validate these initial findings. 
I did not observe alterations between ALS and controls with respect to CRABP-II and 
nuclear receptor interaction via co-immunoprecipitation.  Due to low cellular CRABP-II levels 
and multiple RAR binding partners, the reverse co-immunoprecipitation experiment was not 
successful.  I suggest that downstream interactions between RA (ligand), RARβ (receptor) and 
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nuclear response element (RARE) may explain the altered subcellular distribution we observed 
in motor neurons of sporadic ALS patients rather than upstream protein-protein interactions. 
Although RA signaling has been shown to mediate apoptosis in a variety of cells [249, 
253-255], this pathway has also been shown to inhibit apoptosis in specific cell types [239, 240, 
242].  I propose that redistribution of RARβ to motor neuron nuclei represents a regenerative 
response as RARβ has been shown to mediate neurite outgrowth and neurotrophic effects of RA 
[252].  The observed negative correlation between nuclear RARβ and TUNEL or activated 
caspase-3 suggests that RA signaling through RARβ is a pro-survival response.  In fact, RARβ-
mediated pro-survival and regenerative responses have been reported in models of spinal cord 
and axonal injury [228, 230, 256, 257].  More specifically, neurite outgrowth and functional 
recovery were demonstrated from peripheral nervous system (PNS) tissue (dorsal root ganglia) 
following laminectomy [228].  In the adult rat spinal cord, neurite outgrowth could be stimulated 
by transfection with RARβ2, one of the RARβ isoforms [230]. 
The downstream effects of RA occur via an RAR isotype- and isoform-specific manner 
as nuclear receptor diversity is at least partially responsible for the pleiotrophic effects of RA.  
Several genes known to be modulated by RA have been implicated in motor neuron disease 
including various cytokines, growth factors and the amyloid precursor protein (APP) [258].  
Studies in ALS patients indicate that APP is overexpressed in deltoid muscle biopsies and that 
Aβ42 accumulation occurs in lumbar spinal cord motor neurons [259, 260].  Amyloid deposition 
and plaque formation have been reported in post-mortem brain and spinal cord tissues of ALS 
patients [261].  In addition, matrix metalloproteases (MMPs), which are modulated by RA, have 
been shown to be increased in both the serum and cerebrospinal fluid of ALS patients [262-264].  
Treatment with an MMP-inhibitor extended survival in the transgenic G93A mutant SOD1 
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mouse model of ALS [265].  In addition, the more rapid non-genomic effects of RA signaling 
and interaction of retinoid signaling proteins with mitochondria further link retinoid signaling 
with mechanistic pathways associated with ALS.  The interplay between these proteins and 
pathways and their connection to ALS warrants further investigation.  The downstream signaling 
cascades initiated by RARβ in motor neurons are also of great interest as they may provide novel 
insights into the molecular mechanisms underlying ALS.   
The intracellular distribution of the RARs is an indicator of their transcriptional activity 
[266, 267].  This localization is believed to be determined, in part, by the presence of ligand.  
Previous reports suggest that approximately 80% of unliganded RARβ was localized to the 
nucleus while over 95% of fluorescent-tagged RARβ translocated to the nucleus in the presence 
of RA [268].  Moreover, nucleocytoplasmic shuttling of RARβ is energy-mediated and shuttling 
out of the nucleus was prevented by co-expression of RXR.  Although both ligand binding and 
receptor heterodimerization are required for transcriptional activation, only heterodimerization is 
necessary to ensure proper binding to retinoic acid response elements.  Based on the tissue-
specific expression of the RXRs [269], I expect RXRβ (expressed in most tissues) and possibly 
RXRγ (expressed mostly in muscle and brain) to heterodimerize with RARβ in the spinal cord.  I 
did not observe differences in the localization of RXRβ in spinal cord motor neurons between 
control and ALS subjects (data not shown).  Additional studies are required to define the nuclear 
receptor binding partners of RARβ in motor neurons.  However, it is possible that, in the absence 
of RA, RARβ remains bound to the response element within the gene promoter where it 
functions as a strong transcriptional repressor [161].   
Recent studies have demonstrated that the nucleic acid binding proteins TDP-43 (43 kDa 
TAR DNA-binding protein) [270, 271] and FUS (fused in sarcoma) or TLS (translocation in 
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liposarcoma) [56, 272] exhibit altered nucleocytoplasmic distribution in motor neurons of many 
ALS patients.  Therefore, I examined lumbar spinal cord motor neurons from sporadic ALS 
patients to determine if increased nuclear RARβ occurs in motor neurons harboring TDP-43 
inclusions.  We failed to co-localize increased nuclear RARβ in motor neurons with cytoplasmic 
TDP-43 inclusions suggesting that these two pathologies occur independently. 
Prior studies to investigate the role of retinoid signaling proteins, RARs and RXRs in 
chronic spinal cord degeneration failed to identify the alterations in subcellular distribution 
described in this report (comparison outlined in Figure 33).  For example, Jokic and colleagues 
observed diffuse RARα and RARβ immunostaining in lumbar spinal cord motor neurons at pre-
symptomatic stages which declined in end-stage disease in a rat model of ALS [205].  A similar 
decline in RARα immunoreactivity was reported in rats fed a vitamin A-deficient diet [206].  
Although I was unable to perform a longitudinal study of RARs in human tissue samples, I did 
not observe a difference between ALS and control subjects with respect to the level or 
subcellular localization of RARα.  I believe this is due, at least in part, to mechanistic differences 
between the transgenic SOD1 animal models of ALS and the human disease.  Such differences in 
basic biologic pathways between ALS animal models and the human disease may help explain 
the many failed human clinical trials when the drug candidate successfully modified the disease 
in animal models.  While acknowledging the limitations to this human tissue-based study, I feel 
that observations made in ALS tissue samples are vital and necessary to help interpret findings in 
transgenic models and facilitate future in vitro studies. 
I also acknowledge that protein extraction from spinal cord tissue includes glial cells that 
contribute to both the immunblotting and DNA-binding studies.  However, these cells impact 
motor neuron survival [273] and are able to respond to RA signaling [274].  In fact, cells within 
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the white matter were immunopositive for RARα and RARβ suggesting that they were 
responding to the disease process.  The issue of cell type heterogeneity will be addressed in 
future studies using a combination of laser capture microdissection and quantitative real-time 
polymerase chain reaction to determine protein and mRNA levels on an individual cell basis. 
The shared clinical and pathological features of sporadic and familial forms of ALS are 
well-established and indicate common underlying disease mechanism(s).  Most unexpectedly, 
my study of the retinoid signaling pathway has identified an instance in which sporadic and 
familial forms of the disease may differ.  In particular, altered localization of two key 
components of the retinoid signaling pathway (CRABP-II and RARβ) were observed in spinal 
cord motor neurons of patients with sporadic ALS.  This difference in localization also appeared 
to translate to an increase in binding at the RARE in spinal cord extracts in ALS.  Increased 
nuclear RARβ in lumbar spinal cord motor neurons may increase the ability of these cells to 
survive in the spinal cord microenvironment during ALS as it did not correlate to markers of 
apoptosis.  My findings add to the growing amount of evidence supporting a role for retinoid 
signaling in the pathophysiology of ALS.  Additional work is required to elucidate the exact 
function of the aforementioned nuclear receptors in motor neuron survival and death and to 
determine if pharmacologic modulation of specific receptor activity (i.e., stimulating RARβ-
mediated signaling) can protect motor neurons and serve as effective therapeutic targets. 
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Figure 33.  Schematic Representation of Retinoid Signaling in Familial and Sporadic ALS 
In rodent models of familial ALS, an increase in RXRα has been noted along with declines in 
both RARα and RARβ in end-stage disease.  RXRβ has also been detected in the lumbar spinal 
cord.  In the current study, I noted an increase in the nuclear localization of RARβ in patients 
with sporadic ALS.  Nuclear CRABP-II and cytoplasmic RARα localization were also observed.  
Finally, spinal cord tissue homogenates from patients with ALS were able to bind at the 
consensus RARE suggesting modulation of downstream gene expression.  Pharmacologic agents 
that stimulate this receptor may be promising therapeutic targets that could delay the motor 
neuron cell death that occurs in ALS, thereby slowing the progression of this devastating 
disease. 
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4.0  RETINOIC ACID RECEPTOR-MEDIATED SIGNALING IN MOTOR 
NEURONS 
4.1 ABSTRACT 
The work of our group and others suggests that alterations in the retinoid signaling pathway may 
contribute to the motor neuron cell death that occurs in ALS.  More specifically, the increase in 
nuclear localization of RARβ in motor neurons of patients with sporadic forms of ALS 
(described in Chapter 3) warrants further investigation to determine the functional significance of 
this alteration.  As the RARs are well-established and critical transcription factors, the need for a 
system in which the subcellular localization and downstream effects of these proteins can be 
evaluated in longitudinal studies is necessary.  For these endeavors, I established a primary 
motor neuron-enriched cell culture system.  Initially, mRNA and protein expression were 
characterized with polymerase chain reaction (PCR) and immunofluorescence, respectively.  
Hydrogen peroxide (H2O2) was then used as a model of oxidative-induced cell damage to 
determine the effects of modulating the retinoid signaling pathway on motor neuron cell 
survival/death.  Both RARα and RARβ were expressed in this in vitro system as was observed in 
human lumbar spinal cord.  RARα was localized to processes while RARβ localization was 
observed at the cell body and nucleus.  When motor neurons were cultured in the absence of 
retinoic acid (RA), cell viability was decreased and increased cell death was demonstrated in the 
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presence of toxic insult.  Pre-treatment with a pan-RAR or RARβ-specific agonist decreased 
motor neuron cell death associated with oxidative injury/stress while an RARβ-specific 
antagonist resulted in increased cell death.  Delays in motor neuron cell death were also observed 
when these agonists were administered after H2O2 treatment.  Modulation of downstream targets 
of the RARs (specifically RARβ) has been confirmed using quantitative PCR.  My results 
suggest that signaling through RARβ can promote motor neuron cell survival in the presence of a 
toxin relevant to ALS.  
4.2 INTRODUCTION 
4.2.1 Retinoid Signaling and Limitations of Human Study 
The genomic effects of the retinoid signaling pathway are mediated by the retinoic acid receptors 
(RARs) and the retinoid X receptors (RXRs) [212, 213].  These nuclear receptors function as 
ligand-activated transcription factors, modulating gene expression via binding at retinoic acid 
response elements (RAREs) in the promoter regions of downstream genes [161].  Although both 
all-trans retinoic acid (ATRA) and 9-cis-retinoic acid (9-cis-RA) serve as ligands, ATRA is the 
predominant isomer and activates only the RARs (9-cis-RA activates both RARs and RXRs).  
This signaling pathway is further outlined in Figure 23 and in Chapter 3. 
 While the alterations in the retinoid signaling pathway observed in ALS patients 
discussed in Chapter 3 suggest a role for this pathway in ALS disease pathogenesis, the clinical 
samples analyzed provide only a snapshot of the motor neuron degeneration and death that 
occurs at end-stage ALS as post-mortem samples were utilized.  As this remains a complex and 
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incompletely understood process, further characterization of retinoid signaling, particularly in the 
context of motor neuron cell biology, is required.  More specifically, deciphering the impact of 
the RARs on motor neuron cell survival/death and the downstream genes modulated by each of 
the RAR isotypes is of interest.  For these studies, primary motor neuron-enriched cultures from 
rats offered many advantages including:  1.) increased embryo size as compared to mice; 2.) 
established protocols for isolation and culture; and 3.) the option to utilize transgenic animals 
(i.e., mutant SOD1 and mutant TDP-43 animal models). 
4.2.2 Oxidative Stress 
Motor neuron damage as a result of oxidative stress is a key hypothesis underlying ALS.  The 
fact that oxidative damage increases with age is consistent with the average middle-life onset of 
the disease.  In addition, several studies have confirmed the presence of elevated oxidative 
metabolism in ALS including the detection of increased biochemical markers of oxidative injury 
in post-mortem samples from patients [275].  Increased lipid peroxidation products have also 
been detected in both the plasma [276, 277] and CSF [278] of ALS patients.  In mutant SOD1 
(mSOD1) transgenic mice, elevated levels of protein and lipid oxidation at pre-symptomatic and 
post-symptomatic stages has been observed [279], and mSOD1 can catalyze the production of 
reactive oxygen species (ROS) like superoxide anions (O2
-
), peroxynitrite (ONOO
-
) and 
hydroxyl radicals (OH-) [9]. 
 Oxidative stress may also overlap with other mechanisms thought to contribute to ALS.  
For example, excitotoxicity results in increased levels of intracellular calcium which leads to 
increased nitric oxide (NO) formation.  The reaction of superoxide anions (O2
-
) with nitric oxide 
generates peroxynitrite (ONOO-) which can lead to oxidative damage [280].  Nitration may also 
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target neurofilament proteins, disrupting their phosphorylation status and negatively affecting 
axonal transport [281]. 
 Connections between vitamin A and its derivatives and oxidative stress are suggested by 
a number of studies including those describing their role as antioxidants and radical scavengers 
[282, 283].  For example, RA has been shown to reduce susceptibility to oxidative stress in a 
variety of cell types [239-242] and treatment with RA reduced oxidative stress and apoptotic 
damage in primary cultures from neonatal rat hippocampus [243].  When vitamin A is depleted, 
the resulting mode of cell death has been characterized by increased ROS formation [284, 285] 
and activation of poly-(ADP-ribose) polymerase (PARP)-1, a nuclear protein that acts as a sensor 
of DNA damage [286] and regulator of transcription, cell cycle and cell death [287].  In addition, 
inhibition of RA synthesis in human astrocytoma cells suggests that glutamate metabolism, lipid 
metabolism, mitochondrial function and oxidative stress responses are altered in the absence of 
RA [288].  Taken together, these studies suggest that RA plays a role in the antioxidant defense 
system and deficiencies can exacerbate or cause cell damage/death.     
4.2.3 Study Objectives 
As described in Chapter 3, we have observed alterations in the retinoid signaling pathway in 
patients with ALS.  The increase in the amount of CRABP-II and RARβ localized to the nucleus 
of motor neurons of sporadic ALS patients coupled with an increase in RARE binding in ALS 
patients suggests that the impact of these alterations occurs at the level of transcription.  
Therefore, we sought to establish a model system with which to further study the retinoid 
signaling pathway and its impact on motor neuron survival/death.  In particular, we sought to 
 104 
investigate the functional consequences of modulating the RARs and the ability of these agents 
to promote motor neuron survival in the presence of a toxic insult relevant to ALS. 
4.3 MATERIALS AND METHODS 
4.3.1 Motor Neuron-Enriched Culture System 
Motor neurons were isolated from the spinal cords of Sasco Sprague-Dawley rat embryos at 
gestation day 14 (E14) as previously described [289-291].  Briefly, following removal of the 
spinal cords, tissue was trypsinized and the dissociated cells spun over a metrizamide density 
gradient.  Cells above the metrizamide layer (larger, dense motor neurons) were collected and 
brought up in serum-free growth medium.  Neurobasal base media (Invitrogen, Carlsbad, CA) 
was supplemented with B27 (variations +/- RA) (Invitrogen), BDNF, CNTF and GDNF 
(Peprotech, Rocky Hill, NJ), and as described [289, 290].  Motor neurons were plated in 24-well 
culture trays coated with poly-D lysine (PDL) and then human placental laminin (HPL) at a 
density of approximately 12,000 cells/well.  Cultures were incubated at 37
o
C at 5% CO2 and half 
of the culture supernatant exchanged with fresh medium after 24 hours and every 2 to 3 days 
thereafter. 
4.3.2 RA Pathway Modulators 
All-trans retinoic acid (ATRA) was obtained from Sigma (St. Louis, MO).  Adapalene (RARβ 
and RARγ agonist) and LE-135 (RARβ antagonist) were obtained from Tocris Bioscience 
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(Ellisville, MO).  Stock solutions were prepared in dimethyl sulfoxide (DMSO) such that a 
constant concentration of 0.1% DMSO was present for all treatment groups.  Motor neuron-
enriched cultures were either pre-treated with these agents for approximately 1 hour prior to the 
addition of hydrogen peroxide (H2O2) or treated with these agents approximately 30 minutes 
after the addition of H2O2. 
4.3.3 RNA Extraction 
Motor neurons were plated on 100-mm dishes coated with PDL and HPL as described above.  
Cells were cultured in media with and without RA in the B27 supplement.  For RARβ 
stimulation, cells were treated with 2.5 µM adapalene for 0, 4 or 6 hours prior to RNA 
extraction.  After a brief wash with PBS, RNA was extracted using the Qiagen RNeasy Kit 
(Valencia, CA) per the manufacturer’s instructions.  RNA (1.0 µg) was reverse-transcribed to 
complementary DNA (cDNA) using SuperScript III reverse transcriptase (Invitrogen) prior to 
analysis by real-time PCR.  Products were resolved on 1.5% agarose gels and visualized with 
ethidium bromide. 
4.3.4 Quantitative Polymerase Chain Reaction 
Reactions were carried out in triplicate using 2.5 µL of cDNA/reaction.  RNA was analyzed 
using primers specific to the gene of interest (Table 6) and SYBR Green master mix (Applied 
Biosystems, Carlsbad, CA) in 25 µL reactions.  All PCR reactions were performed using an 
Applied Biosystems 7300 system.  Expression of cyclophilin was used as the endogenous control 
and RAR expression at 1 day in vitro in the absence of retinoic acid served as the reference 
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sample (1 DIV –RA).  The JM2 cell line was a gift from G. Michalopoulos; RNA from these 
cells was used as a positive control.  
4.3.5 Immunofluorescence 
At the designated time points, cells were washed briefly with PBS and fixed in ice cold methanol 
for 2 minutes.  Non-specific binding was blocked with 10% serum after which primary 
antibodies diluted in 2.5% serum were added for approximately 1 hour.  Primary antibodies 
include β3-tubulin (TU-20; 1:300; mouse monoclonal; Santa Cruz Biotechnology, Santa Cruz, 
CA), glial fibrillary acidic protein (GFAP; 1:250; mouse monoclonal; Sigma), RARα (C-20; 
1:300; rabbit polyclonal; Santa Cruz Biotechnology) and RARβ (C-19; 1:300; rabbit polyclonal; 
Santa Cruz Biotechnology).  After a brief wash with PBS, fluorophore-conjugated secondary 
antibodies (goat anti-mouse Alexa Fluor 555 and goat anti-rabbit Alexa Fluor 488) diluted in 
2.5% serum were added for approximately 1 hour and DAPI (4’, 6-diamidino-2-phenylindole) 
used as the nuclear stain. 
4.3.6 Cell Viability/Live Cell Imaging 
After 24 hours in culture, motor neurons were treated with the RA pathway modulators described 
above (ATRA final concentrations of 1.0, 10 or 100 µM; adapalene final concentrations of 0.25, 
2.5 or 25 µM; LE-135 final concentrations of 1.0, 10 or 100 µM) in combination with 400 µM 
H2O2.  Propidium idiodide (PI) was added at a final concentration of 1 µL/500 µL medium.  
Cells were kept in 24-well plates in a previously described time-lapsed microscopic imaging 
system (Automated Cell, Pittsburgh, PA) where bright-field and fluorescent images were 
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acquired every 10 minutes [292].  These images were analyzed using NIH Image J software and 
the number of cells in the bright-field and PI-positive cells quantified at 0, 4, 6, 12, 18, 24, 36, 
48, 60 and 72 hour time points.  The percentage of cell death at these time points was then 
determined for each treatment.  For a typical experiment, each treatment was added to three 
wells and three separate fields averaging 10-20 cells each were counted per well.  The percentage 
of cell death was determined for each field by binning at the indicated time points, and each 
experiment repeated at least twice. 
4.3.7 Statistical Analysis 
Comparisons between treatment groups was accomplished using two-way analysis of variance 
(ANOVA) followed by Bonferroni post-tests.  A p value ≤ 0.05 was considered statistically 
significant. 
4.4 RESULTS 
4.4.1 Expression of RARs in primary cultures 
The procedure for purifying spinal motor neurons was modified from that of Camu and 
Henderson [293, 294] and utilized a density gradient to separate low-density cells from the spinal 
cord cell suspension.  The purity of these preparations was assessed after 48 hours in culture with 
β3-tubulin, a neuron-specific cytoskeletal marker and determined to be 79.5 ± 5.4% neuronal 
cells (Figure 34).  The remaining cells were glial fibrillary acidic protein (GFAP)-positive 
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astrocytes and cluster of differentiation 68 (CD68) was not detected at either the mRNA or 
protein level. 
 
Figure 34.  β3-tubulin Expression and Motor Neuron Culture Purity 
Immunofluorescence images of primary motor neuron-enriched cultures established from E14 
rats after 1 day in vitro (1 DIV; top panel) or 4 DIV (bottom panel).  β3-tubulin was used as a 
neuronal cytoskeletal marker and to assess the purity of the cultures.  Scale bars represent 10 
µm.  
Initially, it was necessary to determine which of the RARs were expressed in this in vitro 
system, and PCR and immunofluorescence were used to characterize mRNA and protein 
expression, respectively.  Using the primers listed in Table 6, RARα and RARβ but not RARγ 
expression was detected (Figure 35A).  When motor neurons were cultured in media with and 
without RA in the B27 supplement for 1, 4 or 7 days in vitro (DIV), the levels of these receptors 
differed as determined by Q-PCR.  That is, expression of RARα was increased at 4 and 7 DIV 
even in the absence of RA (Figure 35B) while RARβ expression decreased with time (Figure 
35C).  The expression of these two nuclear receptors was also confirmed at the protein level 
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(Figure 36) with RARα localization observed in processes (Figure 36, top panel) and RARβ 
protein expression localized predominantly to the cell body and nucleus (Figure 36, bottom 
panel).   
 
Figure 35.  In Vitro RAR Expression 
Expression of the three RAR isotypes was evaluated in the motor neuron-enriched cell culture 
system.  A:  Polymerase chain reaction (PCR) analysis of RNA isolated from primary motor 
neuron cultures after 24 hours in culture.  RARα and RARβ but not RARγ were expressed.  B and 
C:  Quantitative PCR (Q-PCR) analysis of RARα (B) and RARβ (C) expression at 1, 4 and 7 
days in vitro (DIV) in media with and without RA.  RARα expression is increased at 4 and 7 DIV 
while RARβ expression decreases with time and in the absence of media containing RA.  RAR 
expression was normalized to expression at 1 DIV in the absence of RA and cyclophilin 
 110 
expression used as an endogenous control.  “MN” denotes RNA from primary motor neurons; 
“+” denotes RNA isolated from JM2 cells used as a positive control.  Error bars represent the 
mean ± standard deviation for triplicate wells of one experiment. 
  
Table 6.  Primers Utilized for In Vitro Experiments  
 Forward Primer Reverse Primer 
RARα 5’-GGCTACCACTATGGGGTTAGCGC-3’ 5’-GGTTCCGGGTCACCTTGTTGAT-3’ 
RARβ 5’-AGTCATCGGGCTACCACTATGGC-3’ 5’-AGCACTTCTGCAGGCGGCA-3’ 
RARγ 5’-CATTTGAGATGCTGAGCCCCA-3’ 5’-CATACAAAGCACGGCTTATAGACCC-3’ 
Cyp26a1 5’-GCAAGGACGCACTGCAGCTCTT-3’ 5’-GTCCTCGTGATGGCTCTTGCAA-3’ 
CREB 5’-AGACAACCAGCAGAGTGGAGATGC-3’ 5’-GAGACTGAATAACTGATGGCTGGGC-3’ 
HoxA1 5’-TAACTCCTTATCCCCTCTCCACGC-3’ 5’-AACTCCTTCTCCAGCTCTGTGAGCT-3’ 
HoxB1 5’-AACTTTGCATCAGCCTACGATCTCC-3’ 5’-GGCGCGGCTCAGGTATTTGTT-3’ 
Cyclophilin 5’-CCCCACCGTGTTCTTCGACA-3’ 5’-CCCAGTGCTCAGAGCACGAAA-3’ 
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Figure 36.  Characterization of RAR Protein Expression 
Immunofluorescence images of primary motor neuron-enriched cultures established from E14 
rats after 4 days in vitro (4 DIV).  RARα (top panel) is expressed and protein localization 
observed in processes.  RARβ (bottom panel) protein expression is localized predominantly to 
the cell body with some nuclear staining.  Scale bars represent 10 µm. 
4.4.2 Absence of RA in media results in decreased motor neuron cell viability 
As vitamin A deprivation has been characterized by increased ROS formation and oxidative 
stress implicated in ALS disease pathogenesis, H2O2 was used as a model of oxidative 
stress/injury to determine the effect of stimulating the RARs on motor neuron cell survival.  
After 24 hours in culture, cells were treated with increasing concentrations of toxin and a dose-
response curve established (Figure 37).  The concentration used for subsequent experiments (400 
µM H2O2) resulted in approximately 50% cell death after approximately 24 hours.  
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Figure 37.  Hydrogen Peroxide Dose Response Curve 
Motor neuron cultures were treated with various concentrations of H2O2 and cell death 
monitored using live cell imaging and propidium iodide staining over time.  Subsequent 
experiments utilized the concentration that resulted in 50% cell death at approximately 24 hours 
(400 µM).  Error bars represent the mean percentage of cell death ± the standard error of the 
mean from at least 10 motor neurons in 6 different fields from at least 2 different wells for at 
least 2 separate experiments. 
 The impact of the presence of RA in the B27 used as a supplement to the media was then 
evaluated.  Although all other media components were included, eliminating RA resulted in 
decreased cell viability at the 24 hour time point and thereafter (Figure 38A) as assessed by live 
cell imaging/propidium iodide staining.  This increased cell survival in the presence of RA was 
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also demonstrated in the presence of toxin as the absence of RA resulted in statistically 
significant increases in the percentage of cell death throughout the time course (Figure 38B).  
 
Figure 38.  Decreased Cell Death in the Presence of RA 
The percentage of motor neuron cell death was evaluated using live cell imaging and propidium 
iodide staining over 72 hours.  A:  The presence of RA in the B27 media supplement resulted in 
decreased cell death as compared to motor neurons cultured in the absence of RA.  B:  When 
treated with H2O2 as a model of oxidative stress/injury, the absence of RA resulted in 
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significantly increased percentages of cell death.  Error bars represent the mean percentage of 
cell death ± the standard error of the mean from at least 10 motor neurons in 6 different fields 
from at least 2 different wells for at least 2 separate experiments.  *p < 0.05; ***p < 0.001.   
4.4.3 Stimulating the RARs significantly delays oxidative-induced cell death 
The ability of ATRA, a pan-RAR agonist, to protect motor neurons from toxin-induced cell 
death was then evaluated.  As only RARα and RARβ are expressed in this in vitro system, we 
sought to evaluate the ability of these receptors to prevent motor neuron cell death.  When cells 
were pre-treated with 10 µM ATRA, the percentage of cell death was significantly decreased as 
compared to the control-treated cells (Figure 39).  Protein expression for RARα and RARβ for 
this treatment was also assessed, and the co-localization of each of these nuclear receptors with 
β3-tubulin is shown (Figure 40).  RARα appears to be localized to cells that lack β3-tubulin 
expression (Figure 40, A and B, top panels) while co-localization between this neuronal marker 
and RARβ is observed (Figure 40, A and B, bottom panels).  There does not appear to be a 
difference in RAR protein localization when motor neurons are treated with ATRA. 
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Figure 39.  ATRA Treatment Decreases Oxidative-Induced Motor Neuron Cell Death 
Motor neuron-enriched cultures were pre-treated with ATRA for approximately 1.0 hour and 
then H2O2 administered to cause cell death.  ATRA was able to significantly decrease the 
percentage of cell death as compared to the control treatment.  Error bars represent the mean 
percentage of cell death ± the standard error of the mean from at least 10 motor neurons in 6 
different fields from at least 2 different wells for at least 2 separate experiments.  *p < 0.05; **p 
< 0.01; ***p < 0.001. 
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Figure 40.  Localization of RARα and RARβ with and without ATRA Treatment 
Motor neurons cultured in the absence or presence of ATRA.  A:  In the absence of ATRA, RARα 
(top panel) and RARβ (bottom panel) protein localization was evaluated.  B:  When treated with 
10 µM ATRA for 24 hours, RARα (top panel) and RARβ (bottom panel) protein localization was 
assessed.  Although both nuclear receptors are expressed, RARα appears to localize 
predominantly to non-neuronal cells (β3-tubulin negative).  RARβ and β3-tubulin co-localization 
is observed for the majority of cells.  No difference is protein localization is observed when 0 µM 
are 10 µM ATRA treatments are compared.  Scale bars represent 10 µm. 
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Specific agonists and antagonists of RARβ were then used to determine if modulating 
only this receptor could recapitulate the protective effects observed with a pan-agonist that 
stimulated both RARα and RARβ.  When pre-treated for 1.0 hour with adapalene (an RARβ (and 
RARγ) agonist) prior to the addition of H2O2, the percentage of cell death was again significantly 
decreased as compared to the control treatment (Figure 41A).  However, when motor neuron-
enriched cultures were pre-treated for 1.0 hour with an RARβ-selective antagonist (LE-135), the 
percentage of cell death was significantly increased over control treatment (Figure 41B). 
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Figure 41.  RARβ Modulation 
Motor neuron cultures were pre-treated for approximately 1.0 hour with agents that specifically 
target RARβ prior to the addition of toxin.  A:  In the presence of adapalene, an RARβ agonist, 
the percentage of cell death was decreased.  B:  When cells were pre-treated with a combination 
of ATRA and LE-135, an RARβ-selective antagonist, the percentage of cell death was 
significantly increased.  Error bars represent the mean percentage of cell death ± the standard 
error of the mean from at least 10 motor neurons in 6 different fields from at least 2 different 
wells for at least 2 separate experiments.  *p < 0.05; ***p < 0.001. 
To address a clinically-relevant treatment which would be administered after the 
initiation of disease-causing events, agonists and antagonists were administered after toxin 
treatment.  In these experiments, there were also significant delays in motor neuron cell death at 
early time points for ATRA and adapalene (Figure 42).  However, in the presence of the RARβ-
specific antagonist, cell death was increased as compared to the control (Figure 42) indicating 
that cell death is exacerbated when signaling through this receptor is inhibited. 
 
 119 
Figure 42.  Treatment with RA Pathway Modulators after Toxin 
Motor neurons were treated with agonists and antagonists of the RA signaling pathway 
approximately 30 minutes after toxin.  Cell death was monitored with live cell imaging using 
propidium iodide staining over time.  When treated with pan-agonist (10 µM ATRA), motor 
neuron cell death was delayed (stippled bars).  In the presence of adapalene, the percentage of 
cell death was also decreased (horizontal-striped bars).  When an RARβ antagonist was 
administered following toxic insult, the percentage of cell death was significantly increased 
(vertical-striped bars) compared to untreated controls (solid bars).  Error bars represent the 
mean percentage of cell death ± the standard error of the mean from at least 10 motor neurons 
in 6 different fields from at least 2 different wells for at least 2 separate experiments.  *p < 0.05; 
**p < 0.01; ***p < 0.001. 
4.4.4 Downstream targets are modulated by agonists 
Finally, to confirm that alterations in gene expression occurred following stimulation with RARβ 
agonists, mRNA expression of downstream targets of the different RAR isotypes was assessed 
(Figure 43; primers listed in Table 6).  After 24 hours in culture, motor neurons were treated with 
adapalene and RNA extracted at 0, 4 and 6 hour time points.  Expression of cyclic AMP (cAMP) 
response element-binding (CREB), a downstream target of RARβ, was increased over this time 
period (Figure 43).  A slight increase in cytochrome P450 26A1 (Cyp26a1) expression was also 
observed at 4 and 6 hours.  However, expression of homeobox B1 (HoxB1), a downstream target 
of RARα, was unchanged while homeobox A1 (HoxA1), a downstream target of RARγ, was not 
detected. 
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Figure 43.  Q-PCR Analysis of Downstream Genes of the RARs 
Q-PCR was used to assess the expression of genes modulated by the RARs.  After treatment with 
2.5 µM adapalene, an RARβ-specific agonist, for 0, 4 or 6 hours, RNA was extracted and 
primers specific for each downstream target used to determine mRNA expression (Table 6).  
Expression of CREB was increased over this time period and Cyp26a1 expression was also 
increased after 4 and 6 hours of treatment.  Expression of HoxB1 (a downstream target of RARα) 
did not change with adapalene treatment and HoxA1 (a downstream target of RARγ) was not 
detected.  Error bars represent the mean ± standard error of the mean for wells run in triplicate.  
*p < 0.05. 
 121 
4.5 DISCUSSION 
Evidence supporting a role for altered retinoid signaling in ALS continues to accumulate in both 
animal models of the disease [204-206] and ALS patients [199-203].  Although our work using 
spinal cord tissue from ALS patients and control subjects supports these findings, it is unclear 
how this signaling pathway contributes to motor neuron degeneration and/or death.  In addition, 
the role of this signaling pathway, particularly the nuclear receptors, in motor neuron cell biology 
post-development has not been delineated.  To address these unknowns, we utilized a primary 
motor neuron-enriched cell culture system which we combined with live cell imaging to 
investigate the role of the RARs which mediate the genomic effects of RA. 
 Initially, it was necessary to determine whether retinoid receptors were expressed in this 
motor neuron culture system.  Obviously, it was critical that the nuclear receptor expression 
observed in human lumbar spinal cord was recapitulated in this in vitro system.  This was 
demonstrated at both the mRNA and protein levels and suggests that this system serves as an 
accurate representation for the current and future studies designed to determine the impact of 
these nuclear receptors.  Importantly, the localization of these proteins was consistent with what 
we have observed in human lumbar spinal cord motor neurons.  That is, RARα appears to 
localize to processes and, to a lesser extent, the cell body while RARβ localization is observed 
mainly in the cell body and nucleus.  The fact that RARα and RARβ were expressed by non-
neuronal (β3-tubulin negative) cells is also consistent with what we have observed in human 
spinal cord tissue. 
Interestingly, an increase in the expression of RARα was observed from 1 to 7 DIV using 
Q-PCR.  Although we have enriched for motor neurons, GFAP-positive astrocytes account for 
approximately 15-20% of the cells in this system.  As we have also observed RARα protein 
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expression predominantly in non-neuronal cells, this increase in expression is likely due to 
proliferation of these cells (while the population of post-mitotic motor neurons decreases as a 
result of cell death).  The impact of RAR-mediated signaling in these cells has not been 
characterized extensively although a recent study in which RA synthesis was inhibited in a 
human astrocytoma cell line found altered expression of proteins involved in glutamate 
metabolism, lipid metabolism, mitochondrial function and oxidative stress response [288].  
Astroglial cells have also been shown to activate RA synthesis [295] and to be RA-responsive 
[296, 297].  In addition, astroglia-derived RA has been shown to play a key role in glial-induced 
neurogenesis [298].  As astrocytes regulate the extracellular environment, stabilize cell-cell 
communications in the CNS and interact closely with neurons during development and in 
adulthood, the role of these cells can be further studied by modulating the percentage of 
astrocytes in co-culture with motor neurons. 
 The fact that motor neuron cell viability was decreased in the absence of RA was 
surprising considering the multitude of growth factors and supplements included in the media.  
However, this suggests that RA is critical for motor neuron survival and that the neuroprotective 
properties of RA can prevent cell death in the presence of oxidative damage.  Extending these 
studies to include pan-RAR and RARβ-specific agonists indicates that RARβ is responsible for 
mediating these protective effects.  As RARβ was localized predominantly to neuronal cells, this 
RAR isotype may more directly impact motor neuron cell survival.  This protective effect may 
be mediated, at least in part, by cAMP-dependent signaling pathways as had been observed in 
adult dorsal root ganglion neurons in which expression of a particular isoform of this RAR 
isotype (i.e., RARβ2) modulated cAMP-protein kinase A (PKA) pathways [228].  As elevated 
cAMP concentrations [299-301] as well as the activation of CREB protein [302] have been 
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shown to correlate with an enhanced regenerative capacity in the adult CNS, RARβ-mediated 
gene expression may initiate or contribute to a pro-survival response.  Moreover, inhibition of 
RARβ exacerbated motor neuron cell death, suggesting that up- or down-regulation of specific 
downstream targets may prevent this response.  A microarray study to determine which genes are 
downstream of both RARα and RARβ would be useful in understanding the role of each of these 
RAR isotypes. 
The results of other studies suggest that decreased RARα may more directly impact 
motor neuron cell survival at end-stage disease.  For example, in post-mortem lumbar spinal cord 
motor neurons of patients with ALS, loss of RARα expression [206, 230] and transcriptional 
down-regulation of RARα have been reported in the remaining/surviving motor neurons [202].  
In a rat model of ALS, this RARα down-regulation was associated with the selective loss of large 
(> 600 µm
2
) motor neurons.  While we have not distinguished between motor neurons based on 
size as previously described [303], RARα is localized predominantly to non-neuronal cells in our 
in vitro system which may represent a difference between this model and what is observed in 
patients or animal models.  Further characterization of both isotypes is worthwhile as specific 
effects and/or cell types are likely influenced by each. 
The fact that both ATRA and adapalene could extend motor neuron survival following 
toxic insult suggests that these agents could be useful therapeutically.  Although the effects were 
modest and occurred at early time points, it may be that stimulating the RARs (or RARβ 
specifically) may be most effective when initiated early in the disease process as has been 
suggested with riluzole.  It is also possible that this type of treatment would best protect motor 
neurons that have not yet been affected by the disease.  In addition, this therapeutic intervention 
would likely be used in combination with other pharmacologic agents such that increased RAR-
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mediated signaling would be only one aspect of an optimal treatment.  Although adapalene (an 
FDA-approved agent) has been used in humans with few and relatively minor side effects, this 
has been as a topical treatment for acne [304].  However, an internal adapalene delivery system 
has been used for the treatment of cervical intraepithelial neoplasia without side effects [305] 
although an ALS-relevant therapy would require an analog that could cross the blood-brain 
barrier.  This has yet to be evaluated although a variety of RARβ agonists exist that could be 
modified for these purposes.  An intraventricular delivery system similar to the pump utilized in 
the ceftriaxone trial would be another possibility. 
In addition to the classical modulation of gene expression, receptors and proteins of the 
retinoid signaling pathway have other more rapid, non-genomic effects which could be further 
investigated [217, 306].  The three cytoplasmic binding proteins discussed in Chapter 3 (CRBPI, 
CRABP-I and CRABP-II) are expressed in this system (data not shown), and these proteins have 
been shown to associate with the mitochondria [224].  As the mitochondria has been suggested 
as a target of vitamin A regulation [285] and mitochondrial dysfunction implicated in ALS 
disease pathogenesis, the role of this organelle and its connection to RA signaling could be 
evaluated using co-localization studies. 
Several additional studies concerning the differential regulation of retinoid-regulated 
genes support a role for this signaling pathway in the pathogenesis of ALS.  For example, 
increased levels of the amyloid precursor protein (APP) have been detected in deltoid muscle 
biopsies from patients with ALS and in the muscle of G93A SOD1 transgenic mice at pre-
symptomatic stages [260].  The gene that encodes APP is modulated by RA [258], and vitamin A 
has been shown to be anti-amyloidogenic in vitro [307].  In addition, expression of SOD1 (under 
basal conditions) and cytokines like vascular endothelial growth factor (VEGF) are modulated by 
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the retinoid receptors [258, 308].  Finally, we have observed decreased levels of transthyretin 
(TTR), a protein involved in the transport of retinol through its interaction with retinol-binding 
protein, in the cerebrospinal fluid of ALS patients [150].  Therefore, TTR impacts the amount of 
retinol available to cells of the CNS and decreased levels may translate to diminished transport 
function.  Interestingly, RXRs have been shown to interfere with nuclear factor-kappa beta (NF-
κβ) binding to DNA although this transrepression is RXR ligand-dependent [309].  The observed 
up-regulation of the p65 subunit of NF-κβ (RelA) in lumbar spinal cord motor neurons of ALS 
patients [202] may indicate increased NF-κB-dependent transcription in the absence of RXR 
ligand and an indirect role for the retinoid receptors in immune modulation.   
These in vitro studies indicate the importance of retinoid signaling in motor neuron cell 
survival and highlight the ability of agonists of the nuclear receptors to protect motor neurons 
from cell death in the presence of oxidative stress/damage.  Importantly, the primary motor 
neuron-enriched culture system utilized can be used to accurately model RAR-mediated 
signaling as the nuclear receptors expressed in vitro are the same as those observed in human 
lumbar spinal cord motor neurons.  In addition and in combination with live cell imaging, time 
course studies as well as morphological assessments can be captured without the ―black box‖ 
phenomenon often encountered with cell culture work.  Although many additional studies can be 
pursued using this experimental system, the current results are encouraging.  By stimulating 
RARβ, we were able to increase motor neuron cell survival in an environment relevant to ALS.  
This suggests that this nuclear receptor could be of value in the treatment of ALS most likely by 
delaying motor neuron degeneration and death, thereby slowing disease progression.  Future 
drug screens to identify compounds that activate RARβ could be performed first in NSC-34 cells 
with confirmation in this primary culture/live cell imaging system. 
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5.0  FUTURE DIRECTIONS AND CONCLUDING REMARKS 
5.1 ADDITIONAL TTR STUDIES 
Our observations concerning oxidative post-translational protein modifications of TTR and the 
relation of these modifications to storage conditions are somewhat puzzling.  It is difficult to 
rationalize how the apparent oxidation of TTR can be ―reversed‖ to alter the amount of particular 
modified forms of the protein after a sample is moved from -20
o
C to -80
o
C.  As this phenomenon 
was observed in CSF, it would be worthwhile to further investigate these post-translational 
protein modifications in spinal cord tissue homogenates from ALS patients and controls.  As 
with the CSF studies, TTR can be immunoprecipitated from tissue extracts and analyzed via 
mass spectrometry.  In addition to MALDI-TOF-MS, liquid chromatography-tandem mass 
spectrometry (LC-MS/MS) can be used for the identification of post-translational modifications 
to peptide fragments.  High-performance liquid chromatography (HPLC) could also be used to 
isolate TTR prior to mass spectrometry-based analyses.  It is also possible that these changes 
occur as a result of aggregation state and that this can be reversed by temperature.  To investigate 
this possibility, urea could be used to denature the protein or purified TTR could be added to 
determine if it is retained in the aggregates.       
Additional studies of the observed high molecular weight TTR species is also of interest.  
As protein aggregation is known to occur in motor neurons of patients with ALS, determining 
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the role and contribution of these TTR species to the formation of such aggregates is warranted.  
Following immunoprecipitation or HPLC-mediated isolation of TTR from CSF and spinal cord 
tissue extracts, non-denaturing gel conditions could be used to determine if molecular weights 
higher than expected (55 kDa for the native homotetramer) exhibit TTR immunoreactivity.  In 
formalin-fixed human tissue, immunoelectron microscopy can be used to determine if TTR 
aggregates or fibrils are present and if these aggregates/fibrils are located within motor neurons.  
Paraffin-embedded sections could also be used for immunohistochemistry.  In this case, Congo 
red would be used to detect fibrillar proteins enriched in the β-sheet conformation.  Serial 
sections would then be immunostained for TTR to determine if co-localization of TTR and 
Congo red-labeled fibrils occurs and if this is increased in spinal cord tissue of patients with ALS 
as compared to controls. 
Complementary studies in the animal models of familial ALS can also be pursued, and 
we are currently collaborating with a group in Wisconsin that investigates TTR in mouse models 
of AD.  In these studies, our goals are to determine if TTR post-translational modifications 
and/or protein aggregates are detectable in different transgenic SOD1 mutant mouse models.  
Plasma and spinal cord tissue from animals with the G93A, G85R or H46R/H48Q mutations will 
be obtained at disease onset and terminal stage disease.  Initially, the plasma will be analyzed via 
mass spectrometry to determine if the modifications observed in humans are present in the 
animal model.  The level of total TTR protein will also be quantified using ELISA to determine 
if TTR is decreased in animal models of familial ALS as observed in ALS patients and if 
changes in total TTR protein amount occur over time.  Paraffin-embedded spinal cord tissue will 
be used for immunohistochemistry and tissue extracts used for TTR protein isolation followed by 
immunoblotting and mass spectrometry. 
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Finally, the effect of TTR on motor neuron survival can be examined using our primary 
motor neuron-enriched cell culture/live cell imaging system.  TTR immunopreciptated or 
otherwise purified from the CSF or spinal cord tissue extracts of ALS patients and healthy 
controls can be added to motor neurons and the effects on cell survival monitored over time.  
Purified recombinant TTR would serve as a control.  The effects of modulating intracellular TTR 
levels can also be examined using a combination of adenoviral-mediated transduction and 
lentivirus-mediated short hairpin RNA (shRNA) gene knock-down.  These studies can be 
performed in the presence or absence of toxic insults including H2O2-induced oxidative damage 
or glutamate-mediated excitotoxicity.  The neuroprotective properties of intracellular TTR could 
then be evaluated (i.e., its protein chaperone function) along with the downstream signaling 
pathways modulated by TTR (i.e., retinoid signaling).  The interaction between NF-κB-
dependent and RA-mediated gene expression could be another focus of these studies as RXRs 
have been shown to interfere with NF-κB binding to DNA [309], and we hypothesize that 
extracellular TTR could impact both transcription factors (see Figure 22 above).  The ligand-
dependent transrepression observed between NF-κB and RXR could impact a variety of 
biological processes including immune modulation [309].  For example, if extracellular TTR 
remains in complex with RBP-retinol, the transport of retinol and subsequent cellular 
metabolism to 9-cis-RA would preserve RXR ligand availability and result in the formation of a 
transcriptionally inhibitory complex and down-regulation of NF-κB-dependent gene 
transcription.  Conversely, if TTR is confined to protein aggregates and transport function 
diminished, the lack of RXR ligand coupled with activation of Toll-like receptors (TLRs) could 
lead to increased NF-κB-dependent transcription and an increased or exacerbated immune 
response. 
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5.2 TISSUE-BASED WORK 
The increased nuclear localization of RARβ in motor neurons of patients with sporadic ALS is 
certainly worthy of further pursuit.  Laser-capture microdissection and Q-PCR could be used to 
determine if RA-responsive genes are up-regulated in motor neurons with increased nuclear 
RARβ.  These studies would also address the issue of isotype specificity allowing for the 
identification of downstream signaling cascades modulated by RARβ and providing novel 
insight into the role of this transcription factor in ALS and in other conditions (i.e., spinal cord 
and peripheral nerve injuries) in which RARβ-mediated signaling has been shown to play a role.  
Obviously, additional cases should be analyzed to determine if the alterations that we 
have observed in sporadic cases are unique to a subset of patients and to determine if familial 
forms of the disease lack these changes.  A critical aspect of these studies would include 
genotyping of all cases included in the tissue bank.  As TDP-43 and SOD1 pathologies do not 
appear to overlap, it may be that increased nuclear RARβ is indicative of another subtype of 
ALS.  It has been postulated that ALS comprises a spectrum of diseases, and the ability to define 
these subgroups could have clinical implications that impact management, treatment and 
outcomes.    
Immunofluorescence and confocal microscopy could be used to identify the RXR 
isotypes expressed in motor neurons and for co-localization studies with RARβ.  In addition, 
immunoelectron microscopy could be used to determine if components of this signaling pathway 
localize to particular subcellular compartments (i.e., the mitochondria) as these interactions have 
been observed in other cell types.  Extracellular and intracellular localization of TTR can be 
evaluated in these patients to determine if changes in TTR correlate with altered CRABP-II and 
RARβ localization.  Similarly, cellular (uptake) receptors as well as metabolizing enzymes can 
 130 
be further investigated although our results suggest that alterations occur at the level of 
transcription (and not upstream). 
5.3 IN VITRO STUDIES 
5.3.1 Investigation of other ALS-relevant toxins 
In addition to H2O2-mediated oxidative injury, a number of other toxins can be tested to 
determine if modulating the retinoid signaling pathway is protective.  The most obvious choice 
would be to investigate glutamate-mediated excitotoxicity as this is the disease mechanism 
targeted by riluzole therapy.  We have established dose-response curves in our preliminary 
studies and could utilize the available therapy alone or in combination with retinoid pathway 
modulators to determine if there is synergy between these agents.   
CNS injury directly leads to the release of inflammatory signals [310] and RA has been 
shown to have direct neurotrophic effects on neurons with anti-inflammatory effects on 
microglia and astrocytes demonstrated in cell culture experiments [252].  More specifically, 
signals shown to be down-regulated by retinoids include IL-1α, IL-1β, IL-6, TNFα, IL-8 
prostaglandin E2, production of reactive oxygen species and release of lysosomal enzymes [310].  
Therefore, testing the effects of immune modulation (i.e., pro- and anti-inflammatory cytokines, 
lipopolysaccharide) using motor neurons co-cultured with glial cells would be of interest as these 
supporting cells can contribute to motor neuron cell death in ALS and have been shown to 
respond to retinoid signaling [274].   
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5.3.2 Hypoxia 
The oxygenation state of cultured cells is another area of interest, and we have performed 
preliminary experiments to determine if localization of the retinoid receptors is altered as a result 
of non-physiologic oxygen conditions.  In particular, we evaluated the localization of RARα and 
RARβ in 1 DIV motor neurons cultured in the presence or absence of RA after 0, 6, 24, 48 or 72 
hours in a 0% oxygen chamber.  In these studies, there did not appear to be a difference in 
protein localization as a result of anoxia although neuronal processes were largely absent at later 
time points (24 hours and later).  Subsequent studies looking at earlier time points could be 
performed to determine if changes in protein localization and gene expression occur.  If axonal 
processes are affected, agents that stimulate neurite outgrowth could be tested as could 
established or potential neuroprotectants including RARβ agonists.  In addition, low (i.e., 1%, 
3%, 10%, etc.) oxygen levels and intermittent periods of hypoxia could be examined instead of 
anoxia.   
These studies are of increasing interest as a number of genes downstream of hypoxia 
inducible factor-1 (HIF-1) have been linked to ALS.  Genetic variations in both vascular 
endothelial growth factor (VEGF) and angiogenin (ANG) have been identified.  In humans, 
variations in the VEGF gene have been shown to increase the risk of ALS [62] while studies in 
the SOD1 mutant mouse model demonstrated prolonged survival and slower rates of disease 
progression with VEGF treatment [120, 311].  Missense mutations in the ANG gene have also 
been identified in patients with ALS [312], and ANG has been shown to protect motor neurons 
against hypoxic injury [313].  Interestingly, the neuroprotective properties of ANG were lost 
when ALS-associated SOD1 mutants were expressed in a motor neuron-like cell line indicating 
that an abnormal response to hypoxia occurs in patients with ALS [313]. 
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Erythropoietin (EPO) can also be induced by hypoxia and has been shown to have 
neuroprotective effects in hypoxic-ischemia brain injury in neonatal rats [314].  A study 
comparing EPO levels in normoxemic and hypoxemic (oxygen arterial blood pressure below the 
age-dependent minimal reference value) ALS patients and controls found increased levels of 
EPO in hypoxemic ALS patients compared to normoxemic ALS patients and controls [315].  
This study proposed that EPO was acting at multiple levels including limiting production of 
tissue-damaging molecules like reactive oxygen species (ROS) and stimulating angiogenesis 
[315]. 
Connections between RNA processing and hypoxia may also impact the disease process.  
Hypoxia has been shown to up-regulate VEGF expression by increasing transcription and via 
post-transcriptional regulation of VEGF mRNA.  The identification of a 126-base hypoxia 
stability region (HSR) in the 3’ untranslated region (UTR) of the human VEGF gene suggests 
that hypoxia-inducible mRNA-protein complexes contribute to increased VEGF expression 
[316].  In addition, interactions between the VEGF HSR and heterogeneous nuclear 
ribonucleoprotein L (hnRNP L), a global regulator of alternative splicing, play an important role 
in hypoxia-induced regulation of VEGF mRNA stability [317].   
The interdependence of immune and hypoxic responses to infection and tissue damage is 
another area of interest.  HIF expression is up-regulated through pathways involving the key 
immune response regulator, NF-κB [318], and studies in patients with ALS have questioned 
whether elevated levels of certain cytokines indicate inflammation or hypoxia [319].  Two 
additional studies provide a link between mechanisms thought to underlie ALS, hypoxia and the 
immune system.  In the first, chronic hypoxia was shown to suppress carrier-mediated glutamate 
uptake in astrocytes by suppressing EAAT1 and EAAT2 (2 major glutamate transporters) 
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expression [320].  Inhibition of transporter expression was later shown to require NF-κB 
activation and to be modulated by TNFα with TNFα production enhanced by hypoxia [321].  As 
dysfunction of EAAT2 has been implicated in ALS, the relationship between hypoxia and 
glutamate-mediated excitotoxicity could be further studied in our in vitro system. 
5.3.3 Neurite outgrowth and regeneration 
RA signaling is implicated in neurite regeneration [256, 257], and several mediators of the RA 
signaling pathway are induced after peripheral nerve injury including CRBPI, CRABP-II and 
RALDH2 [322].  Interestingly, local activation of the RARE was reported in regenerating nerves 
of transgenic reporter mice following sciatic nerve injury suggesting that RA-mediated gene 
expression is induced during this regenerative process [322].  The same group demonstrated 
increased expression of the nuclear receptors (RARs and RXRs) at both the mRNA and protein 
levels following sciatic nerve crush [323].  Cell culture experiments indicate that RARβ is 
required for this axonal regeneration [257, 324], and further studies to characterize the effects of 
RARβ on neurite outgrowth could be performed in this in vitro system.  In our preliminary 
experiments using all-trans retinoic acid (ATRA) as a pan-RAR agonist, we assessed a number 
of morphological characteristics on a per cell basis including:  1.) number of neurites, 2.) number 
of branch points, 3.) length of the longest neurite and 4.) total neurite area.  We observed a 
statistically significant decrease in the number of branch points/cell with increasing 
concentrations of ATRA.  While intriguing, these studies need to be repeated ideally with green 
fluorescent protein (GFP)-tagged markers of neuronal cells (i.e., β3-tubulin) to enable 
identification of neuronal processes. 
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5.3.4 Non-genomic impact of retinoid signaling 
In addition to the classical modulation of gene expression, receptors and proteins of the retinoid 
signaling pathway have other more rapid, non-genomic effects [217, 306].  Specifically, the 
impact on phosphatidylinositol-3-kinase (PI3K) and extracellular signal-regulated kinase (ERK) 
mitogen-activated protein kinase (MAPK) signaling pathways could be determined by measuring 
phosphorylation of Akt kinase and ERK1/2, respectively.  Interactions between retinoid 
signaling components and the mitochondria [224] as well as modulation of mitochondrial gene 
expression by retinoids (reviewed in [223]) have also been observed.  As mitochondrial 
dysfunction is one mechanism thought to play a role in ALS disease pathogenesis, it would be 
interesting to perform co-localization studies and to assess these interactions in the presence of 
toxins or when specific agonists/antagonists are administered. 
5.3.5 Microarray analysis of downstream genes 
As discussed for the human tissue-based study, the genes regulated by the retinoid receptors 
could be investigated in this in vitro system.  This would enable the identification of genes 
downstream of the RARs in an isotype-specific manner.  In addition, a microarray study would 
be useful for determining which genes are up- or down-regulated and could uncover novel 
pathways underlying ALS or support further research into previously-identified mechanisms.  As 
a great deal remains to be determined regarding the role of this signaling pathway post-
development, this information would extend beyond ALS. 
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5.3.6 Role and effects of glial cells 
It is well-established that ALS is a disease of not only the motor neurons but their non-neuronal 
neighbors.  In our culture system, the predominant non-neuronal cell is the glial fibrillary acidic 
protein (GFAP)-positive astrocyte.  Therefore, studies utilizing varying percentages of these cells 
in co-culture with the motor neurons could help determine the contribution of these cells in the 
context of retinoid signaling. 
5.3.7 Investigation of other potential biomarkers 
The overall goal of the Bowser laboratory is to identify proteins that are differentially-expressed 
or modified in the CSF (or plasma) of patients with ALS.  Although the retinoid signaling 
pathway is obviously one avenue worth pursuing, there are multiple other candidate biomarkers 
in need of study.  A few examples identified via mass spectrometry-based proteomics include:  
the complement system (part of the innate immune system) with components shown to be up-
regulated in the CSF of ALS patients; ceruloplasmin (an enzyme involved in copper binding and 
oxidation of iron) which was shown to be up-regulated in ALS CSF; antithrombin (a serine 
protease inhibitor involved in coagulation) which is decreased in ALS CSF; cystatin C (a 
cysteine protease inhibitor) which is decreased in ALS CSF [150, 325]; and the carboxy-terminal 
protein fragment of the 7B2 protein (7B2-CT; an indirect inhibitor of hormone and neuropeptide 
maturation) shown to be increased in ALS CSF [150].  As multiple pathways and categories of 
proteins have been identified in these studies with unclear roles in motor neuron cell function, 
this in vitro system will enable the impact of these alterations to be investigated and understood 
at the cellular level.  
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5.3.8 Primary cultures from transgenic mutant SOD1 or mutant TDP-43 rats 
Finally, the differences we have observed between sporadic and familial ALS patients are ones 
for which we still do not have a definitive explanation.  In an attempt to provide insight into how 
retinoid signaling impacts at least a fraction of the familial forms of the disease, transgenic 
mutant SOD1 or mutant TDP-43 rats can be used to generate primary motor neuron-enriched 
cultures.  Initial characterization of the localization of RARα and RARβ would determine if the 
presence of the mutated proteins alone results in altered subcellular distribution.  Subsequent 
studies would focus on the impact of either mutant protein in the presence of the toxins discussed 
above and the ability (or inability) of RARβ agonists to protect toxin-exposed cells.  In this way, 
we can begin to define the relationship between SOD1, TDP-43 and the retinoid signaling 
pathway and to rationalize why increased nuclear localization of CRABP-II and RARβ does not 
occur in motor neurons from patients with familial forms of the disease. 
5.4 CONCLUDING REMARKS 
Ultimately, my goal was to establish an experimental system with which to expedite the 
transition from bench discoveries to the bedside.  Although all experimental systems and 
approaches have limitations, the approach we have taken begins where it will eventually end—
with the patient.  Identification of protein alterations that occur in patients with a predominantly 
idiopathic disease combined with the ability to determine the functional consequences of these 
alterations at the level of the motor neuron could enable the translation of these findings to early 
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stages of clinical trials once drugs that target proteins/pathways of interest are developed and 
proven in our in vitro system.  
The data presented suggest that the retinoid signaling pathway is altered in patients with 
ALS and that modulating this pathway can promote motor neuron survival in the presence of 
oxidative-induced cell death.  The latter experiments are especially encouraging as protection 
was observed at low doses of RARβ agonist and indicate that RARβ-mediated signaling is 
neuroprotective.  Importantly, the increase in RARβ nuclear localization observed in spinal cord 
motor neurons of patients with sporadic ALS could result in transcriptional repression (and lack 
of neuroprotection) in the absence of ligand (outlined in Figure 44).  Therefore, agonists of this 
nuclear receptor could be used therapeutically to delay the motor neuron degeneration and death 
that occurs in ALS thereby slowing disease progression in patients with this devastating disease. 
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Figure 44.  TTR and the Transcriptional Impact of Nuclear RARβ 
Alterations in the amount of TTR in patients with ALS impact the amount of ligand available to 
the retinoid receptors.  Left:  When TTR is abundant, retinol (which circulates in complex with 
TTR and RBP) is available for uptake at the cell surface.  Once inside the cell, the action of 
dehydrogenases converts available retinol to (predominantly) all-trans retinoic acid which binds 
to RARβ to activate transcription of downstream targets.  Right:  Decreased levels of TTR in the 
CSF would translate to a lack of retinol available for cellular uptake.  Without retinol and in the 
absence of ligand, nuclear RARβ remains bound to retinoic acid response elements where it acts 
as a transcriptional repressor. 
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